Document:

Exhibit 10.1

 

SUBSCRIPTION
AGREEMENT

 

This
Subscription Agreement (this “Agreement”), dated as of _____, 2021, has been executed by the purchaser set
forth on the signature page hereof (the “Purchaser”), in connection with the private placement offering (the
“Offering”), in one or more closings, of up to $1,000,000 of shares (each, a “Share”
and, collectively, the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”),
of Blue Star Foods Corp., a Delaware corporation (the “Company”), at a purchase price of $2.00 per Share (the
“Purchase Price”). In addition, in connection with the Purchaser’s purchase of Shares in the Offering,
the Purchaser will receive a three-year warrant, in substantially the form attached hereto as Exhibit A (each, a “Warrant”
and, collectively, the “Warrants”), representing the Purchaser’s right to purchase additional shares
of the Company’s Common Stock (the “Warrant Shares”) equal to the number of Shares subscribed for by
such Purchaser, at an exercise price of $2.00 per share.

 

The
Shares being subscribed for pursuant to this Agreement have not been registered under the U.S. Securities Act of 1933, as amended (the
“Securities Act”). The Offering is being made on a reasonable best-efforts basis to “accredited investors,”
as defined in Regulation D under the Securities Act, in reliance upon the exemption from securities registration afforded by Section
4(a)(2) of the Securities Act and/or Rule 506 of Regulation D. The minimum subscription per investor is $2,500.

 

The
initial closing and any subsequent closings of the purchase and sale of the Shares shall be referred to as a “Closing,”
and the date on which such Closing occurs hereinafter referred to as the “Closing Date”, and shall take place
at the offices of The Crone Law Group P.C. (the “Escrow Agent”), at 500 Fifth Avenue, Suite 938, New York, New York, 10110,
or at such other locations or remotely by facsimile transmission or other electronic means as the parties may mutually agree. Each Closing
will not occur unless the conditions set forth in Article V shall have been satisfied.

 

ARTICLE
I.

PURCHASE AND SALE

 

1.1.
Subscription. The undersigned Purchaser hereby subscribes to purchase the number of Shares set forth on the signature page attached
hereto (the “Omnibus Signature Page”), for the aggregate Purchase Price as set forth on such Signature Page,
subject to the terms and conditions of this Agreement and on the basis of the representations, warranties, covenants and agreements contained
herein. At the effective time of the Closing, the Purchaser shall also receive a Warrant to purchase such number of Warrant Shares as
is set forth on the Signature Page attached hereto.

 

1.2
Subscription Procedure. To complete a subscription for the Shares, the Purchaser shall review, complete and execute the Omnibus
Signature Page to this Agreement together with the Accredited Investor Certification, attached hereto following the Omnibus Signature
Page to the address set forth under the caption “How to subscribe for Shares in the private offering of Blue Star Foods Corp.”
below. Executed documents may be delivered by facsimile or .pdf sent by electronic mail (e-mail), if the Purchaser delivers the original
copies of the documents as soon as practicable thereafter. Simultaneously with the delivery of the Transaction Documents (as defined
below), the Purchaser shall deliver to the Escrow Agent, the full Purchase Price, by certified or other bank check or by wire transfer
of immediately available funds, in United States dollars and in immediately available funds, as instructed under the caption “How
to subscribe for Shares in the private offering of Blue Star Foods Corp.” below (the aggregate amounts received being held
in escrow by the Escrow Agent are referred to herein as the “Escrow Amount”). Such funds will be returned promptly,
without interest or offset, if this Agreement is not accepted by the Company or the Offering is terminated pursuant to the terms of this
Agreement prior to the Closing. All funds received from prospective qualified Purchasers will be held in escrow in a non-interest-bearing
account by the Escrow Agent, pending release on the initial Closing Date, a subsequent Closing Date, or the Termination Date, pursuant
to the terms of an Escrow Agreement between the Company, the Escrow Agent and the Subscribers, substantially in the form attached as
Exhibit B hereto (the “Escrow Agreement”).

 

    	 

     

    

 

1.3
Company Discretion. The Purchaser understands and agrees that the Company, in its sole discretion, reserves the right to accept
or reject this or any other subscription for Shares, in whole or in part, notwithstanding prior receipt by the Purchaser of notice of
acceptance of this subscription. The Company shall have no obligation hereunder until the Company shall execute and deliver to the Purchaser
an executed copy of this Agreement. If this subscription is rejected in whole, or the Offering is terminated, all funds received from
the Purchaser will be returned without interest or offset, and this Agreement shall thereafter be of no further force or effect. If this
subscription is rejected in part, the funds for the rejected portion of this subscription will be returned without interest or offset,
and this Agreement will continue in full force and effect to the extent this subscription was accepted.

 

1.4
Closing Deliveries.

 

(a)
On or prior to the Closing, the Company shall issue, deliver or cause to be delivered to the Purchaser the following (the “Company
Deliverables”):

 

(i)
this Agreement, duly executed by the Company; and

 

(ii)
a certificate of the President of the Company (the “Closing Certificate”), dated as of the Closing Date, (a)
certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement
and the other Transaction Documents and the issuance of the Shares, the Warrants, and the Warrant Shares (as these terms are defined
in Section 2.2 below) and (b) certifying to the fulfillment of the conditions specified in Section 5.1,

 

(b)
On or prior to the Closing, each Purchaser shall deliver or cause to be delivered to the Company the following (the “Purchaser
Deliverables”):

 

(i)
this Agreement, duly executed by such Purchaser;

 

(ii)
a fully completed and duly executed Accredited Investor Certification; and

 

(iii)
the full Purchase Price pursuant to the Subscription Procedure specified in Section 1.2.

 

(c)
At the Closing:

 

(i)
the Company shall instruct the Escrow Agent to deliver, in immediately available funds, the Escrow Amount constituting the aggregate
purchase price less the applicable expenses and fees to be paid by the Company;

 

(ii)
the Company shall irrevocably instruct the Company’s transfer agent to deliver to each Purchaser the Shares in book entry, or in
certificate form, if specifically requested by the Purchaser, evidencing the number of Shares such Purchaser is purchasing as is set
forth on such Purchaser’s Omnibus Signature Page within five (5) business days after the Closing; and

 

(iii)
the Company shall deliver to each Purchaser a Warrant to purchase such number of Warrant Shares as is set forth on the Omnibus Signature
Page attached hereto, within five (5) Business Days after the Closing.

 

    	2

     

    

 

ARTICLE
II.

REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 

The
Company hereby represents and warrants to the Purchaser, as of the date hereof and on the Closing Date, the following:

 

2.1
Organization and Qualification. The Company and each of its subsidiaries (the “Subsidiaries”) is a corporation
or other business entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its formation and
has the requisite corporate power to own its properties and to carry on its business as now being conducted. The Company and each of
its Subsidiaries is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which the
nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or
be in good standing would not have a material adverse effect on the assets, business, financial condition, results of operations or future
prospects of the Company or its Subsidiaries (a “Material Adverse Effect”).

 

2.2
Authorization, Enforcement, Compliance with Other Instruments. The Company has the requisite corporate power and authority to
enter into and perform its obligations under this Agreement, the Escrow Agreement and the Warrants (collectively with this Agreement,
the “Transaction Documents”) and to issue the Shares, the Warrants and the Warrant Shares; collectively, the
“Securities”) in accordance with the terms hereof and thereof; the execution and delivery by the Company of
each of the Transaction Documents and the consummation by it of the transactions contemplated hereby and thereby, including, without
limitation, the issuance of the Securities have been, or will be at the time of execution of such Transaction Document, duly authorized
by the Company’s board of directors (the “Board of Directors”), and no further consent or authorization
is, or will be at the time of execution of such Transaction Documents, required by the Company, the Board of Directors or its stockholders;
(iii) each of the Transaction Documents will be duly executed and delivered by the Company; the Transaction Documents when executed will
constitute the valid and binding obligations of the Company enforceable against the Company in accordance with their terms, except as
such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’ rights and remedies.

 

2.3
Capitalization. The number of shares and type of all authorized, issued and outstanding capital
stock, options and other securities of the Company (whether or not presently convertible into or exercisable
or exchangeable for shares of capital stock of the Company) is set forth in the SEC Reports
(as defined below). The Company has not issued any capital stock since the date of its most recently filed SEC Report other than to reflect
stock option and warrant exercises that do not, individually or in the aggregate, have a material effect on the issued and outstanding
capital stock, options and other securities. No person has any right of first refusal, preemptive right, right of participation,
or any similar right to participate in the transactions contemplated by the Transaction Documents that have not been effectively waived
as of the Closing Date. Except as set forth in the SEC Reports, there are no outstanding options, warrants, scrip rights to subscribe
to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable
or exchangeable for, or giving any person, either an individual or an entity, any right to subscribe for or acquire any shares of Common
Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue
additional shares of Common Stock or shares issuable upon conversion or exercise of Common Stock. All of the outstanding shares of capital
stock of the Company are validly issued, fully paid and nonassessable, have been issued in compliance with all applicable federal and
state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe
for or purchase securities. There are no stockholders’ agreements, voting agreements or other similar agreements with respect to
the Company’s capital stock to which the Company is a party or, to the Company’s knowledge, between or among any of the Company’s
stockholders (for the purpose of this Agreement, the knowledge of the Company means the actual knowledge of the officers
of the Company).

 

2.4
Issuance of Shares. The Securities are duly authorized and, when issued and paid for in accordance with the terms hereof, the
Shares and Warrants and, when issued in accordance with the terms of the Warrants, the Warrant Shares, shall be duly issued, fully paid
and nonassessable, and are free and clear of all taxes, liens and charges with respect to the issue thereof, other than restrictions
on transfer provided for in the Transaction Documents or imposed by applicable securities laws, and shall not be subject to preemptive
or similar rights of stockholders. The sale and issuance of the Securities will not obligate the Company to issue shares of Common Stock
or other securities to any person (other than the Purchasers) and will not result in a right of any holder of Company securities to adjust
the exercise, conversion, exchange or reset price under any of such securities other than as set forth in the SEC Reports. No further
approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities.
Assuming the accuracy of the representations and warranties of the Purchasers in this Agreement, the Securities will be issued in compliance
with all applicable federal and state securities laws. As of the Closing Date, the Company shall have reserved from its duly authorized
capital stock a number of shares of Common Stock equal to the number of Warrant Shares. The Company shall, so long as any of the Warrants
are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued capital stock, solely for
the purpose of effecting the exercise of the Warrants, the number of Warrant Shares.

 

    	3

     

    

 

2.5
No Conflicts. The execution, delivery and performance by the Company of the Transaction Documents to which it is a party and the
consummation by the Company of the transactions contemplated hereby or thereby (including, without limitation, the issuance of the Securities
and the reservation for issuance of the Warrant Shares) do not and will not (i) conflict with or violate any provisions of the Company’s
or any Subsidiary’s certificate or articles of incorporation, bylaws or otherwise result in a violation of the organizational documents
of the Company or any Subsidiary, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both
would result in a default) under, result in the creation of any lien upon any of the properties or assets of the Company or any Subsidiary
or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both)
of, any material contract, or (iii) subject to the Required Approvals (as defined in Section 2.12 below), conflict with or result in
a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority
to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations and the rules and regulations,
assuming the correctness of the representations and warranties made by the Purchasers herein, of any self-regulatory organization to
which the Company or its securities are subject, including the Pink Marketplace of OTC Markets, which is the current trading market of
the Company’s Common Stock (the “Trading Market”), or by which any property or asset of the Company or
a Subsidiary is bound or affected, except in the case of clauses (ii) and (iii) such as would not, individually or in the aggregate,
have or reasonably be expected to result in a Material Adverse Effect.

 

2.6
SEC Reports. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by it under
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including pursuant to Section 13(a) or
15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to
file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively
referred to herein as the “SEC Reports”) on a timely basis or has received a valid extension of such time of
filing and has filed any such SEC Reports prior to the expiration of any such extension, except where the failure to file on a timely
basis would not have or reasonably be expected to result in a Material Adverse Effect. As of their respective filing dates, or to the
extent corrected by a subsequent restatement, the SEC Reports complied in all material respects with the requirements of the Securities
Act and the Exchange Act and the rules and regulations of the Securities and Exchange Commission (the “Commission”
or the “SEC”) promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading. Each of the material contracts to which the Company or any
Subsidiary is a party or to which the property or assets of the Company or any of its Subsidiaries are subject has been filed as an exhibit
to the SEC Reports.

 

2.7
Financial Statements. The financial statements of the Company included in the SEC Reports comply in all material respects with
applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing
(or to the extent corrected by a subsequent restatement). Such financial statements have been prepared in accordance with GAAP applied
on a consistent basis during the periods involved, except as may be otherwise specified in such financial statements or the notes thereto
and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects
the financial position of the Company and its consolidated subsidiaries taken as a whole as of and for the dates thereof and the results
of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial year-end
audit adjustments.

 

    	4

     

    

 

2.8
Material Changes. Since the date of the latest audited financial statements included within the SEC Reports, except as specifically
disclosed in a subsequent SEC Report filed prior to the date hereof, (i) there have been no events, occurrences or developments that
have had or would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect, (ii) the Company
has not incurred any material liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the
ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial
statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered materially its method
of accounting or the manner in which it keeps its accounting books and records, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock (other than in connection with repurchases of unvested stock issued to employees of the Company), and (v)
the Company has not issued any equity securities to any “Affiliate”, as such term defined and construed under
Rule 405 under the Securities Act, except Common Stock issued in the ordinary course as dividends on outstanding preferred stock or issued
pursuant to existing Company stock option or stock purchase plans or executive and director compensation arrangements disclosed in the
SEC Reports. Except for the issuance of the Securities contemplated by this Agreement, no event, liability or development has occurred
or exists with respect to the Company or its Subsidiaries or their respective business, properties, operations or financial condition,
that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made that has
not been publicly disclosed at least one (1) one day the Common Stock is quoted on the Trading Market as reported by OTC Markets Group,
Inc (the “Trading Day”) prior to the date that this representation is made.

 

2.9
Absence of Litigation. There is no action, suit, claim, inquiry, notice of violation, proceeding (including any partial proceeding
such as a deposition) or investigation before or by any court, public board, governmental or administrative agency, self-regulatory organization,
arbitrator, regulatory authority, stock market, stock exchange or trading facility (an “Action”) now pending
or, to the knowledge of the Company, threatened, against or affecting the Company or any of its officers or directors, which would be
reasonably likely to (i) adversely affect the validity or enforceability of, or the authority or ability of the Company to perform its
obligations under this Agreement or any of the other Transaction Documents, or (ii) have a Material Adverse Effect. The SEC has not issued
any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any of its Subsidiaries
under the Exchange Act or the Securities Act.

 

2.10
Transactions With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or directors of the Company
and, to the Company’s knowledge, none of the employees of the Company is presently a party to any transaction with the Company
or any Subsidiary (other than for services as employees, officers and directors), that would be required to be disclosed pursuant to
Item 404 of Regulation S-K promulgated under the Securities Act.

 

2.11
Internal Accounting Controls. The Company maintains a system of internal accounting controls sufficient to provide reasonable
assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset and liability accountability,
(iii) access to assets or incurrence of liabilities is permitted only in accordance with management’s general or specific authorization,
and (iv) the recorded accountability for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals
and appropriate action is taken with respect to any differences.

 

2.12
Required Approvals. Neither the Company nor any of its Subsidiaries is required to obtain any consent, waiver, authorization or
order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental
authority or other person in connection with the execution, delivery and performance by the Company of the Transaction Documents (including
the issuance of the Shares, the Warrants and the Warrant Shares), other than (i) filings required by applicable state securities laws,
(ii) the filing of a Notice of Sale of Securities on Form D with the Commission under Regulation D of the Securities Act, (iii) the filing
of any requisite notices and/or application(s) to the Trading Market for the issuance and sale of the Securities and the listing of the
Shares and Warrant Shares for trading or quotation, as the case may be, thereon in the time and manner required thereby, (iv) the filings
required in accordance with Section 4.5 of this Agreement and (v) those that have been made or obtained prior to the date of this Agreement
(collectively, the “Required Approvals”).

 

    	5

     

    

 

2.13
Certain Fees. No person or entity will have, as a result of the transactions contemplated by this Agreement, any valid right,
interest or claim against or upon the Company or a Purchaser for any commission, fee or other compensation pursuant to any agreement,
arrangement or understanding entered into by or on behalf of the Company. The Purchasers shall have no obligation with respect to any
fees or with respect to any claims made by or on behalf of other persons for fees of a type contemplated in this paragraph (r) that may
be due in connection with the transactions contemplated by the Transaction Documents.

 

2.14
No Registration. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Article III
of this Agreement and the accuracy of the information disclosed in the Accredited Investor Questionnaires provided by the Purchasers,
no registration under the Securities Act is required for the offer and sale of the Securities or the issuance of the Securities by the
Company to the Purchasers under the Transaction Documents. The issuance and sale of the Securities hereunder complies in all material
respects with and does not contravene the rules and regulations of the Trading Market.

 

2.15
Investment Company. The Company is not, and immediately after receipt of payment for the Shares, will not be an “investment
company” within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner
so that it will not become subject to the Investment Company Act of 1940, as amended.

 

2,16
Compliance with the Requirements of the Trading Market. The Company has not, in the twelve (12) months preceding the date hereof,
received written notice from any Trading Market on which the Common Stock is listed or quoted to the effect that the Company is not in
compliance with the listing or maintenance requirements of such Trading Market. The Company is in compliance with all requirements of
the Trading Market on the date hereof.

 

2.17
Disclosure. The Company confirms that it has not provided, and to the Company’s knowledge, none of its officers or directors
nor any other person acting on its or their behalf has provided, any Purchaser or its respective agents or counsel with any information
that it believes constitutes material, non-public information except insofar as the existence, provisions and terms of the Transaction
Documents and the proposed transactions hereunder may constitute such information, all of which may be disclosed by the Company in the
Company’s press release related to the Closing. The Company understands and confirms that the Purchasers will rely on the foregoing
representations in effecting transactions in securities of the Company. All written materials provided to the Purchasers regarding the
Company and its Subsidiaries, their businesses and the transactions contemplated hereby, including the schedules to this Agreement, furnished
by the Company or on behalf of the Company or any of its Subsidiaries is true and correct in all material respects and does not contain
any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in
the light of the circumstances under which they were made, not misleading. No event or circumstance has occurred, or information exists
with respect to the Company or any of its Subsidiaries or its or their business, properties, liabilities, prospects, operations (including
results thereof) or conditions (financial or otherwise), which, under applicable law, rule or regulation, requires public disclosure
at or before the date hereof or announcement by the Company but which has not been so publicly disclosed.

 

2.18
No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Article
III, none of the Company, its Subsidiaries nor, to the Company’s knowledge, any of its Affiliates or any person acting on its
behalf has, directly or indirectly, at any time within the past six (6) months, made any offers or sales of any Company security or solicited
any offers to buy any security under circumstances that would (i) eliminate the availability of the exemption from registration under
Regulation D under the Securities Act in connection with the offer and sale by the Company of the Shares as contemplated hereby or (ii)
cause the offering of the Securities pursuant to the Transaction Documents to be integrated with prior offerings by the Company for purposes
of any applicable law, regulation or stockholder approval provisions, including, without limitation, under the rules and regulations
of any Trading Market on which any of the securities of the Company are listed or designated.

 

    	6

     

    

 

2.19
Tax Matters. The Company and each of its Subsidiaries (i) has accurately and timely prepared and filed all foreign, federal and
state income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all
taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports
and declarations, except those being contested in good faith, with respect to which adequate reserves have been set aside on the books
of the Company and (iii) has set aside on its books provisions reasonably adequate for the payment of all taxes for periods subsequent
to the periods to which such returns, reports or declarations apply, except, in the case of clauses (i) and (ii) above, where the failure
to so pay or file any such tax, assessment, charge or return would not have or reasonably be expected to result in a Material Adverse
Effect. There are no unpaid taxes in any material amount claimed to be due by the Company or any of its Subsidiaries by the taxing authority
of any jurisdiction.

 

2.20
No General Solicitation. Neither the Company nor, to the Company’s knowledge, any person acting on behalf of the Company
has offered or sold any of the securities by any form of general solicitation or general advertising.

 

2.21
No Disqualification Events. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under the
Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of
the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company’s outstanding voting equity
securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act)
connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person”) is subject
to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification
Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable
care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable,
with its disclosure obligations under Rule 506(e), and has furnished to the Purchasers a copy of any disclosures provided thereunder.
The Company will notify the Purchasers in writing, prior to the Closing Date of (i) any Disqualification Event relating to any Issuer
Covered Person and (ii) any event that would, with the passage of time, reasonably be expected to become a Disqualification Event relating
to any Issuer Covered Person, in each case of which it is aware.

 

2.22
Foreign Corrupt Practices. Neither the Company, nor to the Company’s knowledge, any agent or other person acting on behalf
of the Company, has: (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses
related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees
or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made
by the Company (or made by any person acting on its behalf with the Company’s knowledge) which is in violation of law or (iv) violated
in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.

 

2.23
Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company (or any Subsidiary)
and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in SEC Reports and is not so
disclosed and would have or reasonably be expected to result in a Material Adverse Effect.

 

2.24
Acknowledgment Regarding Purchasers’ Purchase of the Securities. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated
hereby and thereby. Based on the representations made herein by the Purchasers, the Company further acknowledges that no Purchaser is
acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and
the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection
with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers’ purchase of the
Securities. The Company further represents to each Purchaser that the Company’s decision to enter into this Agreement and the other
Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and
its representatives.

 

    	7

     

    

 

2.25
Regulation M Compliance. The Company has not, and to the Company’s knowledge no one acting on its behalf has, (i) taken,
directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting
purchases of, any of the securities of the Company or (iii) paid or agreed to pay to any person any compensation for soliciting another
to purchase any other securities of the Company.

 

2.26
OFAC. Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director, officer, agent, employee, Affiliate
or person acting on behalf of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department (“OFAC”); and the Company will not directly or indirectly
use the proceeds of the sale of the Shares, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture
partner or other person or entity, towards any sales or operations in Cuba, Iran, Syria, Sudan, Myanmar or any other country sanctioned
by OFAC or for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.

 

2.27
Former Shell Status. Prior to November 8, 2018, the Company has been a “shell company” as defined in Rule 12b-2 under
the Exchange Act.

 

ARTICLE
III.

REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS.

 

Each
Purchaser hereby, for itself and for no other Purchaser, represents and warrants as of the date hereof and as of the Closing Date to
the Company as follows:

 

3.1
Organization; Authority. If such Purchaser is an entity, such Purchaser is duly organized, validly existing and in good standing
under the laws of the jurisdiction of its organization with the requisite corporate or partnership power and authority to enter into
and to consummate the transactions contemplated by the applicable Transaction Documents and otherwise to carry out its obligations hereunder
and thereunder. The execution and delivery of this Agreement by such Purchaser and performance by such Purchaser of the transactions
contemplated by this Agreement have been duly authorized by all necessary corporate or, if such Purchaser is not a corporation, such
partnership, limited liability company or other applicable like action, on the part of such Purchaser. Each Transaction Document to which
it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will
constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except as
such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating
to, or affecting generally the enforcement of, creditors’ rights and remedies or by other equitable principles of general application.

 

3.2
No Conflicts. The execution, delivery and performance by such Purchaser of the Transaction Documents to which such Purchaser is
a party and the consummation by such Purchaser of the transactions contemplated hereby and thereby will not (i) result in a violation
of the organizational documents of such Purchaser, (ii) conflict with, or constitute a default (or an event which with notice or lapse
of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of,
any agreement, indenture or instrument to which such Purchaser is a party, or (iii) result in a violation of any law, rule, regulation,
order, judgment or decree (including federal and state securities laws) applicable to such Purchaser, except in the case of clauses (ii)
and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be
expected to have a material adverse effect on the ability of such Purchaser to perform its obligations hereunder.

 

    	8

     

    

 

3.3
Investment Intent. Such Purchaser understands that the Securities are “restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account and
not with a view to, or for distributing or reselling such securities or any part thereof in violation of the Securities Act or any applicable
state securities laws, provided, however, that by making the representations herein, such Purchaser does not agree to hold any of the
Securities for any minimum period of time and reserves the right, subject to the provisions of this Agreement, at all times to sell or
otherwise dispose of all or any part of such securities pursuant to an effective registration statement under the Securities Act or under
an exemption from such registration and in compliance with applicable federal and state securities laws. Such Purchaser is acquiring
the Securities hereunder in the ordinary course of its business. Such Purchaser does not presently have any agreement, plan or understanding,
directly or indirectly, with any person to distribute or effect any distribution of any of the Securities (or any securities which are
derivatives thereof) to or through any person or entity; such Purchaser is not a registered broker-dealer under Section 15 of the Exchange
Act, or an entity engaged in a business that would require it to be so registered as a broker-dealer.

 

3.4
Accredited Investor Status. The Purchaser is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated
under the Securities Act and the Accredited Investor Certification delivered by the Purchaser in connection with this Agreement is complete
and accurate in all respects as of the date of this Agreement and will be correct as of the Closing Date and the effective date of the
Registration Statement; provided, that the Purchaser shall be entitled to update such information by providing written notice thereof
to the Company.

 

3.5
General Solicitation. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other
communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or
presented at any seminar or any other general advertisement.

 

3.6
Experience of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Securities and, at the present time, is able to afford a complete loss of such investment. Moreover, such Purchaser
is aware that (i) the acquisition of the Securities involves a high degree of risk and may result in a loss of the entire Purchase Price;
(ii) the Company has limited working capital and limited sources of financing available as of the date of this Agreement; (iii) there
is no assurance that the Company’s operations will be profitable or cash flow positive at any time in the future.

 

3.7
Access to Information. Such Purchaser acknowledges that it has had the opportunity to review the SEC Reports, including without
limitation, Part I, Item 1, “Business” and Part I, Item 1A, “Risk Factors,” in the Company’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2019, filed with the Commission on May 29, 2020, and has been afforded (i) the opportunity
to ask such questions as it has deemed necessary of, and to receive satisfactory answers from, representatives of the Company concerning
the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information
about the Company and the Subsidiaries and their respective financial condition, results of operations, business, properties, management
and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that
the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision
with respect to the investment. Neither such inquiries nor any other investigation conducted by or on behalf of such Purchaser or its
representatives or counsel shall modify, amend or affect such Purchaser’s right to rely on the truth, accuracy and completeness
of the SEC Reports and the Company’s representations and warranties contained in the Transaction Documents. Such Purchaser has
sought such accounting, legal and tax advice as it has considered necessary to make an informed decision with respect to its acquisition
of the Securities.

 

    	9

     

    

 

3.8
Certain Trading Activities. Other than with respect to the transactions contemplated herein, since the time that such Purchaser
was first contacted by the Company or any other person regarding the transactions contemplated hereby, neither the Purchaser nor any
Affiliate of such Purchaser which (x) had knowledge of the transactions contemplated hereby, (y) has or shares discretion relating to
such Purchaser’s investments or trading or information concerning such Purchaser’s investments, including in respect of the
Shares, and (z) is subject to such Purchaser’s review or input concerning such Affiliate’s investments or trading (collectively,
“Trading Affiliates”) has directly or indirectly, nor has any person acting on behalf of or pursuant to any
understanding with such Purchaser or Trading Affiliate, effected or agreed to effect any purchases or sales of the securities of the
Company (including, without limitation, any short sales involving the Company’s securities). Notwithstanding the foregoing, in
the case of a Purchaser and/or Trading Affiliate that is, individually or collectively, a multi-managed investment bank or vehicle whereby
separate portfolio managers manage separate portions of such Purchaser’s or Trading Affiliate’s assets and the portfolio
managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s
or Trading Affiliate’s assets, the representation set forth above shall apply only with respect to the portion of assets managed
by the portfolio managers that have knowledge about the financing transaction contemplated by this Agreement. Other than to other persons
party to this Agreement, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction
(including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein
shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or
securing of, available shares to borrow in order to effect short sales or similar transactions in the future in compliance with the Securities
Act and the rules and regulations promulgated thereunder.

 

3.9
Brokers and Finders. No person will have, as a result of the transactions contemplated by this Agreement, any valid right, interest
or claim against or upon the Company or any Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement
or understanding entered into by or on behalf of the Purchaser.

 

3.10
Independent Investment Decision. Such Purchaser has independently evaluated the merits of its decision to purchase the Securities
pursuant to the Transaction Documents, and such Purchaser confirms that it has not relied on the advice of any other Purchaser’s
business and/or legal counsel in making such decision. Such Purchaser understands that nothing in this Agreement or any other materials
presented by or on behalf of the Company to the Purchaser in connection with the purchase of the Shares constitutes legal, tax or investment
advice. Such Purchaser has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate
in connection with its purchase of the Securities. Such Purchaser has not authorized any person or institution to act as Purchaser’s
“purchaser representative” (as such term is defined in Rule 501 of Regulation D promulgated under the Securities Act) in
connection with Purchaser’s acquisition of the Securities.

 

3.11
Reliance on Exemptions. Such Purchaser understands that the Securities are being offered and sold to it in reliance on specific
exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying upon
the truth and accuracy of, and such Purchaser’s compliance with, the representations, warranties, agreements, acknowledgements
and understandings of such Purchaser set forth herein as part of its determination as to the availability of such exemptions and the
eligibility of such Purchaser to acquire the Securities.

 

3.12
No Governmental Review. Such Purchaser understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in
the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

3.13
Regulation M. Such Purchaser is aware that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales
of Common Stock and other activities with respect to the Common Stock by the Purchasers and agrees to comply with such rules.

 

    	10

     

    

 

3.14
Beneficial Ownership. The purchase by such Purchaser of the Securities issuable to it at the Closing will not result in such Purchaser
(individually or together with any other person with whom such Purchaser has identified, or will have identified, itself as part of a
“group” in a public filing made with the Commission involving the Company’s securities) acquiring, or obtaining the
right to acquire, in excess of 4.99% of the outstanding shares of Common Stock or the voting power of the Company on a post transaction
basis that assumes that such Closing shall have occurred. Such Purchaser does not presently intend to, alone or together with others,
make a public filing with the Commission to disclose that it has (or that it together with such other persons have) acquired, or obtained
the right to acquire, as a result of such Closing (when added to any other securities of the Company that it or they then own or have
the right to acquire), in excess of 4.99% of the outstanding shares of Common Stock or the voting power of the Company on a post transaction
basis that assumes that each Closing shall have occurred.

 

3.15
Former Shell Status; Limited Public Market. The Purchaser expressly acknowledges that prior to November 8, 2018, the Company was
a “shell company” as defined in Rule 12b-2 under the Exchange Act. Pursuant to Rule 144(i) under the Securities Act, securities
issued by a current or former shell company that otherwise meet the holding period and other requirements of Rule 144 nevertheless cannot
be sold in reliance on Rule 144 unless at the time of a proposed sale pursuant to Rule 144 the Company is subject to the reporting requirements
of Section 13 or 15(d) of the Exchange Act and has filed all reports and other materials required to be filed by Section 13 or 15(d)
of the Exchange Act, as applicable, during the preceding 12 months (or for such shorter period that the issuer was required to file such
reports and materials), other than Form 8-K reports. As a result, the restrictive legends on the Securities, or if issued in certificated
form, on the certificates for the Securities, cannot be removed except in connection with an actual sale meeting the foregoing requirements
or pursuant to an effective registration statement. The Purchaser further acknowledges and understands that although the Company’s
common stock has been approved for quotation on the OTC pink sheets under the symbol “BSFC” since February 18, 2020, the
Company’s stock has not been listed on any national securities exchange; that currently only a limited public market exists for
the Shares and that there can be no assurance that any public market for the Shares will continue to exist.

 

3.16
Residency. Such Purchaser’s residence (if an individual) or offices in which its investment decision with respect to the
Shares was made (if an entity) are located at the address immediately below such Purchaser’s name on its Omnibus Signature Page
hereto.

 

The
Purchasers acknowledge and agree that no party to this Agreement has made or makes any representations or warranties with respect to
the transactions contemplated hereby other than those specifically set forth in this Article III and the Transaction Documents.

 

ARTICLE
IV.

OTHER COVENANTS AND AGREEMENTS

 

4.1
Transfer Restrictions.

 

(a)
Compliance with Laws. Notwithstanding any other provision of this Article IV, each Purchaser covenants that the Securities
may be disposed of only pursuant to an effective registration statement under, and in compliance with the requirements of, the Securities
Act, or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the Securities
Act, and in compliance with any applicable state and federal securities laws. In connection with any transfer of the securities other
than (i) pursuant to an effective registration statement, (ii) to the Company, (iii) pursuant to Rule 144 (provided that the Purchaser
provides the Company with reasonable assurances (in the form of a legal opinion satisfactory to the Company and, if applicable, broker
representation letters) that the securities may be sold pursuant to such rule), or (iv) in connection with a bona fide pledge as contemplated
in Section 4.1(c), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by
the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to
the Company, to the effect that such transfer does not require registration of such transferred securities under the Securities Act.
As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and shall have the
rights of a Purchaser under this Agreement with respect to such transferred securities.

 

    	11

     

    

 

(b)
Legends. The Securities shall each bear any legend as required by the “blue sky” laws of any state and a restrictive
legend in substantially the following form, until such time as they are not required under Section 4.1(b):

 

NEITHER
THESE SECURITIES NOR ANY SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD,
TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR
(B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY
AND ITS TRANSFER AGENT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER THE SECURITIES ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES
MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

(c)
The Company acknowledges and agrees that a Purchaser may from time-to-time pledge, and/or grant a security interest in, some or all of
the legended securities in connection with applicable securities laws, pursuant to a bona fide margin agreement in compliance with a
bona fide margin loan. Such a pledge would not be subject to approval or consent of the Company and no legal opinion of legal counsel
to the pledgee, secured party or pledgor shall be required in connection with the pledge, but such legal opinion shall be required in
connection with a subsequent transfer or foreclosure following default by the Purchaser transferee of the pledge. No notice shall be
required of such pledge, but Purchaser’s transferee shall promptly notify the Company of any such subsequent transfer or foreclosure.
Each Purchaser acknowledges that the Company shall not be responsible for any pledges relating to, or the grant of any security interest
in, any of the securities or for any agreement, understanding or arrangement between any Purchaser and its pledgee or secured party.
At the appropriate Purchaser’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured
party of securities may reasonably request in connection with a pledge or transfer of the securities. Each Purchaser acknowledges and
agrees that, except as otherwise provided here, any securities subject to a pledge or security interest as contemplated by Section
4.1(c) shall continue to bear the legend set forth in this Section 4.1(b) and be subject to the restrictions on transfer set
forth in Section 4.1(a)

 

(d)
Removal of Legends. The legend set forth in Section 4.1(b) above shall be removed and the Company shall issue a certificate
without such legend or any other legend to the holder of the applicable securities upon which it is stamped or issue to such holder by
electronic delivery at the applicable balance account at the Depository Trust Company (“DTC”), if (i) such
securities are registered for resale under the Securities Act (provided that, if the Purchaser
is selling pursuant to a registration statement, the Purchaser agrees to only sell such securities during
such time that such registration statement is effective and current and not withdrawn or suspended, and only as permitted by such
registration statement), (ii) such securities are sold or transferred pursuant to Rule 144 (if the transferor is not an Affiliate of
the Company) and the Purchaser provides a legal opinion to that effect and such opinion to be satisfactory in the sole discretion of
the Company, or (iii) such securities are eligible for sale under Rule 144, without the requirement for the Company to be in compliance
with the current public information required under Rule 144 as to such securities and without volume or manner-of-sale restrictions.

 

4.2
Reservation of Common Stock. The Company shall take all action necessary to at all times have authorized and reserved for the
purpose of issuance from and after the Closing Date, the number of Warrant Shares issuable upon exercise of the Warrants issued at the
Closing (without taking into account any limitations on exercise of the Warrants set forth in the Warrants).

 

4.3
Furnishing of Information. The Company shall timely file (or obtain extensions in respect thereof and file within the applicable
grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act.

 

    	12

     

    

 

4.4
Integration. The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company
shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the
Securities Act) that will be integrated with the offer or sale of the securities in a manner that would require the registration under
the Securities Act of the sale of the Shares to the Purchasers, or that will be integrated with the offer or sale of the securities for
purposes of the rules and regulations of any Trading Market such that it would require stockholder approval prior to the closing of such
other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.

 

4.5
Securities Laws Disclosure; Publicity. Within four (4) Trading Days after the final Closing, the Company will file a Current Report
on Form 8-K with the Commission describing the terms of the Transaction Documents (and including as exhibits to such Current Report on
Form 8-K the material Transaction Documents (including, without limitation, this Agreement and the form of Warrant)). Notwithstanding
the foregoing, the Company shall not publicly disclose the name of any Purchaser or an Affiliate of any Purchaser, or include the name
of any Purchaser or an Affiliate of any Purchaser in any press release or filing with the Commission (other than the Registration Statement)
or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except to the extent such disclosure
is required by law, request of the Staff of the Commission or Trading Market regulations, in which case the Company shall provide the
Purchasers with prior written notice of such disclosure permitted hereunder. From and after the earlier of the issuance of such Form
8-K and a press release with respect to the Transaction Documents (a “Press Release”), no Purchaser shall be in possession
of any material, non-public information received from the Company, any Subsidiary or any of their respective officers, directors, employees
or agents, that is not disclosed in the Press Release unless a Purchaser shall have executed a written agreement after the issuance of
the Press Release regarding the confidentiality and use of such information. Each Purchaser, severally and not jointly with the other
Purchasers, covenants that until such time as the transactions contemplated by this Agreement are required to be publicly disclosed by
the Company as described in this Section 4.5, such Purchaser will maintain the confidentiality of all disclosures made to it in
connection with this transaction (including the existence and terms of this transaction) and will not trade in the Company’s securities.

 

4.6
Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, including this Agreement, or as expressly required by any applicable securities law, the Company covenants and agrees that
neither it, nor any other person acting on its behalf, will provide any Purchaser or its agents or counsel with any information regarding
the Company that the Company believes constitutes material non-public information without the express written consent of such Purchaser,
unless prior thereto such Purchaser shall have executed a written agreement regarding the confidentiality and use of such information.
The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities
of the Company.

 

4.7
Use of Proceeds. The Company shall use the net proceeds from the sale of the Shares hereunder for working capital and other general
corporate purposes.

 

4.8
Form D; Blue Sky. The Company agrees to timely file a Form D with respect to the securities as required under Regulation D and
to provide a copy thereof, promptly upon the written request of any Purchaser. The Company, on or before the Closing Date, shall take
such action as the Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify the securities for
sale to the Purchasers under applicable securities or “Blue Sky” laws of the states of the United States (or to obtain an
exemption from such qualification) and shall provide evidence of such actions promptly upon the written request of any Purchaser.

 

4.9
Short Sales and Confidentiality After the Date Hereof. Each Purchaser shall not, and shall cause its Trading Affiliates not to,
engage, directly or indirectly, in any purchases and sales of the Company’s securities (including, without limitation, any short
sales involving the Company’s securities) during the period from the date hereof until the earlier of such time as (i) the transactions
contemplated by this Agreement are first publicly announced as required by and described in Section 4.5 or (ii) this Agreement
is terminated in full pursuant to the terms hereof. Each Purchaser, severally and not jointly with the other Purchasers, covenants that
until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company as described in Section 4.5,
such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Transaction
Documents. Notwithstanding the foregoing, no Purchaser makes any representation, warranty or covenant hereby that it will not engage
in Short Sales in the securities of the Company after the time that the transactions contemplated by this Agreement are first publicly
announced as described in Section 4.5.

 

    	13

     

    

 

4.10
Registration Rights.

 

(a)
Piggyback Registration Rights.

 

(i)
Each Purchaser (together with any permitted transferee of such Purchaser, a “Holder”) is hereby granted the
right to “piggyback” the Shares and Warrant Shares (such shares being referred to herein as “Registrable Securities”)
on any registration statement filed by the Company, within two (2) years of the Closing Date, to register equity securities (or other
Company securities convertible, exercisable or exchangeable for Company equity securities) issued by the Company (the “Registration
Statement”), so long as the registration form to be used is suitable for the registration of the Registrable Securities (a “Piggyback
Registration”) (it being understood that the Form S-8 and Form S-4, or any successor forms, may not be used for such purposes),
all at the Company’s cost and expense (except commissions or discounts and fees of any of the Holder’s own professionals,
if any; it being understood that the Company shall not be obligated to pay the fees and expenses of Holder’s counsel); provided,
however, that this paragraph 4.10(a)(i) shall not apply to any Registrable Securities if such Registrable Securities may then be
sold under Rule 144 (assuming the Holder’s compliance with the provisions of the Rule) with the result that the sold securities
are freely tradable without restriction and the Company delivers an opinion to that effect to the transfer agent; and provided, further,
that if the offering with respect to which a Registration Statement is filed is an underwritten primary or secondary offering of the
Company’s securities and the managing underwriter advises the Company in writing that in its opinion the number of securities requested
to be included in such registration exceeds the number that can be sold in such offering without adversely affecting such underwriter’s
ability to effect an orderly distribution of such securities or otherwise adversely effecting such offering (including, without limitation,
causing a diminution in the offering price of the Company’s securities) the Company will include in such Registration Statement:
(1) first, the securities being sold for the account of the Company; (2) second, the number of securities with respect to which the Company
has granted rights to participate in such registration (including the Registrable Securities) that, in the opinion of such underwriter,
can be sold pro rata among the respective holders of such securities on the basis of the amount of such securities then owned by each
such Holder. The Company shall give each Holder of Registrable Securities at least fifteen (15) days written notice of the intended filing
date of any Registration Statement, other than a registration statement filed on Form S-4 or Form S-8, or any successor forms, and each
Holder of Registrable Securities shall have seven (7) days after receipt of such notice to notify the Company of its intent to include
the Registrable Securities in the Registration Statement.

 

(ii)
If, at any time after giving written notice of its intention to register any securities and prior to the effective date of the Registration
Statement filed in connection with such registration, the Company shall determine for any reason not to register or to delay registration
of such securities, the Company may, at its election, give written notice of such determination to all Holders of the Registrable Securities
and (1) in the case of a determination not to register, shall be relieved of its obligation to register any Registrable Securities in
connection with such abandoned registration and (2) in the case of a determination to delay such registration of its securities, shall
be permitted to delay the registration of such Registrable Securities for the same period as the delay in registering such other Company
securities.

 

(b)
Expenses. The Company shall bear all fees and expenses attendant to registering the Registrable Securities (except any underwriters’
discounts and commissions and fees of any of the Holders’ own professionals, if any; it being understood that the Company shall
not be obligated to pay the fees and expenses of Holder’s counsel). The Company agrees to use its best efforts to cause the filing
required herein to become effective promptly and to qualify to register the Registrable Securities in such states as are reasonably requested
by the Holder; provided, however, that in no event shall the Company be required to register the Registrable Securities in a state
in which such registration would cause (1) the Company to be obligated to register or license to do business in such state, (2) subject
the Company to any material tax where it is not then so subject, (C) require the Company to file a general consent to service of process
in such jurisdiction, or (D) the principal stockholders of the Company to be obligated to escrow any of their shares of capital stock
of the Company.

 

    	14

     

    

 

(c)
Indemnification. The Company shall indemnify and hold harmless the Holder of the Registrable Securities to be sold pursuant to
any Registration Statement filed hereunder, and each of such Holder’s officers, directors, employees, agents, partners, legal counsel
and accountants, and each person, if any, who controls each of the foregoing within the meaning of Section 15 of the Securities Act or
Section 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), against all loss, claim,
damage, expense or liability (including all reasonable attorneys’ fees and other expenses reasonably incurred in investigating,
preparing or defending against any claim whatsoever incurred by the indemnified party in any action or proceeding between the indemnitor
and indemnified party or between the indemnified party and any third party or otherwise) to which any of them may become subject under
the Securities Act, the Exchange Act, or any other statute or at common law or otherwise under laws of foreign countries, arising from
such Registration Statement or based upon any untrue statement or alleged untrue statement of a material fact contained in (1) any preliminary
prospectus, registration statement or prospectus (as from time to time each may be amended and supplemented); (2) in any post-effective
amendment or amendments or any new registration statement and prospectus in which is included the Registrable Securities; or (3) any
application or other document or written communication (collectively called “application”) executed by the Company or based
upon written information furnished by the Company in any jurisdiction in order to qualify the Registrable Securities under the securities
laws thereof or filed with the commission, any state securities commission or agency, any national securities exchange; or the omission
or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading; unless such statement or omission is made in reliance upon, and in strict
conformity with, written information furnished to the Company with respect to the Holders expressly for use in a preliminary prospectus,
registration statement or prospectus, or any amendment or supplement thereof, or in any application, as the case may be. The Company
agrees promptly to notify the Holders of the Registrable Securities of the commencement of any litigation proceedings against the Company
or any of its officers, directors or controlling persons in connection with the issue and sale or resale of the Registrable Securities
or in connection with any such registration statement or prospectus.

 

4.11
Anti-Dilution. The Shares shall have anti-dilution protection such that if within twelve (12) months after the final Closing of
the Offering the Company shall issue Additional Shares of Common Stock (as defined below) without consideration, or for a consideration
per share, or with an exercise or conversion price per share, less than the Purchase Price, the Purchaser shall be entitled to receive
from the Company (for no additional consideration) additional Shares in an amount such that, when added to the number of Shares purchased
by Purchaser under this Agreement, will equal the number of Shares that the Purchaser’s Purchase Price for the Shares set forth
on the Purchaser’s Omnibus Signature Page would have purchased at the Adjusted Price (as defined below). For the purpose hereof:

 

(a)
“Adjusted Price” shall mean the price (calculated to the nearest cent) determined by multiplying the Purchase
Price per share in effect immediately prior to such issue (which, for avoidance of doubt, shall be $2.00 prior to the first such issue)
by a fraction, (i) the numerator of which shall be (1) the number of shares of Common Stock outstanding immediately prior to such issue,
plus (2) the number of shares of Common Stock which the aggregate consideration received or to be received by the Company for the total
number of Additional Shares of Common Stock so issued would purchase at such Adjusted Price; and (ii) the denominator of which shall
be (1) the number of shares of Common Stock outstanding immediately prior to such issue, plus (2) the number of such Additional Shares
of Common Stock so issued; provided, however that, (i) for the purpose of this Section 4.11(a), all shares of Common Stock issuable
upon conversion or exchange of convertible securities outstanding immediately prior to such issue shall be deemed to be outstanding,
and (ii) the number of shares of Common Stock deemed issuable upon conversion or exchange of such outstanding convertible securities
shall be determined without giving effect to any adjustments to the conversion or exchange price or conversion or exchange rate of such
convertible securities resulting from the issuance of Additional Shares of Common Stock that is the subject of this calculation; and

 

    	15

     

    

 

(b)
“Additional Shares of Common Stock” shall mean all shares of Common Stock issued by the Company after the first
Closing of the Offering (including without limitation any shares of Common Stock issuable upon conversion or exchange of any convertible
securities or upon exercise of any option or warrant, on an as-converted basis), other than: (i) shares of Common Stock issued or issuable
upon conversion or exchange of any convertible securities or exercise of any options or warrants outstanding as of immediately following
the initial Closing; (ii) shares of Common Stock issued or issuable upon exercise of the Warrants; (iii) shares of Common Stock issued
or issuable by reason of a dividend, stock split, split-up or other distribution on shares of Common Stock relating to any recapitalization,
reclassification or reorganization of the capital stock of the Company, or any consolidation or merger of the Company with another corporation,
or the sale of all or substantially all of its assets or other transaction effected in such a way that there is no change of control;
(iv) shares of Common Stock issued in a firmly underwritten registered public offering under the Securities Act; (v) shares of Common
Stock issued or issuable pursuant to the acquisition of another entity or business by the Company by merger, purchase of substantially
all of the assets or other reorganization or pursuant to a joint venture or technology license agreement, but not including a transaction
in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing
in securities; (vi) shares of Common Stock issued or issuable to officers, directors and employees of, or consultants to, the Company
pursuant to stock grants, option plans, purchase plans or other employee stock incentive programs or arrangements approved by the Board
of Directors, or upon exercise of options or warrants granted to such parties pursuant to any such plan or arrangement; (vii) any securities
issued or issuable by the Company pursuant to the Subscription Agreements in this Offering; and (viii) securities issued to financial
institutions, institutional investors or lessors in connection with credit arrangements, equipment financings, lease arrangements or
similar transactions, in the aggregate not exceeding ten percent (10%) of the number of shares of Common Stock outstanding at any time,
and in case of clauses (iii) through (viii) above, such issuance is approved by a majority of disinterested directors of the Company
and includes no “death spiral” provision of any kind.

 

ARTICLE
V.

CONDITIONS PRECEDENT TO CLOSING

 

5.1
Conditions Precedent to the Obligations of the Purchasers to Purchase Securities. The obligation of each Purchaser to acquire
the Shares at the Closing is subject to the fulfillment to such Purchaser’s satisfaction, on or prior to the Closing Date, of each
of the following conditions, any of which may be waived by such Purchaser (as to itself only):

 

(a)
Representations and Warranties. The representations and warranties of the Company contained herein shall be true and correct in
all material respects (except for those representations and warranties which are qualified as to materiality, in which case such representations
and warranties shall be true and correct in all respects) as of the date when made and as of the Closing Date, as though made on and
as of such date, except for such representations and warranties that speak as of a specific date.

 

(b)
Performance. The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements
and conditions required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing.

 

(c)
No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents.

 

(d)
Consents. The Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers
necessary for consummation of the purchase and sale of the Shares (including all Required Approvals).

 

    	16

     

    

 

(e)
Adverse Changes. Since the date of execution of this Agreement, no event or series of events shall have occurred that has had
or would reasonably be expected to have a Material Adverse Effect, all of which shall be and remain so long as necessary in full force
and effect.

 

(f)
Adverse Changes. Since the date of execution of this Agreement, no event or series of events shall have occurred that has had
or would reasonably be expected to have a Material Adverse Effect.

 

(g)
No Suspensions of Trading in Common Stock. The Common Stock shall not have been suspended, as of the Closing Date, by the Commission
or the Trading Market from trading on the Principal Trading Market nor shall suspension by the Commission or the Principal Trading Market
have been threatened, as of the Closing Date, either (A) in writing by the Commission or the Trading Market or (B) by falling below the
minimum listing maintenance requirements of the Trading Market.

 

(h)
Company Deliverables. The Company shall have delivered the Company Deliverables in accordance with Section 1.4(a).

 

(i)
Compliance Certificate. The Company shall have delivered to each Purchaser a certificate, dated as of the Closing Date and signed
by its Chief Executive Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in Sections
5.1.

 

(j)
Termination. This Agreement shall not have been terminated as to such Purchaser in accordance with the terms hereof.

 

5.2
Conditions Precedent to the Obligations of the Company to sell the Shares. The Company’s obligation to sell and issue the
Shares at the Closing to the Purchasers is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date
of the following conditions, any of which may be waived by the Company:

 

(a)
Representations and Warranties. The representations and warranties made by the Purchasers in Article III hereof shall be
true and correct in all material respects (except for those representations and warranties which are qualified as to materiality, in
which case such representations and warranties shall be true and correct in all respects) as of the date when made, and as of the Closing
Date as though made on and as of such date, except for representations and warranties that speak as of a specific date.

 

(b)
Performance. Such Purchaser shall have performed, satisfied and complied in all material respects with all covenants, agreements
and conditions required by the Transaction Documents to be performed, satisfied or complied with by such Purchaser at or prior to the
Closing Date.

 

(c)
No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents.

 

(d)
Consents. The Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers
necessary for consummation of the purchase and sale of the Shares, all of which shall be and remain so long as necessary in full force
and effect.

 

(e)
Purchasers Deliverables. Such Purchaser shall have delivered its Purchaser Deliverables in accordance with Section 1.4(b).

 

(f)
Termination. This Agreement shall not have been terminated as to such Purchaser in accordance with the terms hereof.

 

    	17

     

    

 

ARTICLE
VI.

MISCELLANEOUS

 

6.1
Fees and Expenses. The Company and the Purchasers shall each pay the fees and expenses of their respective advisers, counsel,
accountants and other experts, if any, and all other expenses incurred by such party in connection with the negotiation, preparation,
execution, delivery and performance of this Agreement. The Company shall pay all applicable fees to the transfer agent, stamp taxes and
other taxes and duties levied in connection with the sale and issuance of the Securities to the Purchasers.

 

6.2
Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding
of the parties with respect to the subject matter hereof and supersede all prior agreements, understandings, discussions and representations,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.
At or after the Closing, and without further consideration, the Company and the Purchasers will execute and deliver to the other such
further documents as may be reasonably requested in order to give practical effect to the intention of the parties under the Transaction
Documents.

 

6.3
Indemnification. The Purchaser agrees to indemnify and hold harmless the Company, and its directors, officers, shareholders, members,
partners, employees and agents (and any other persons with a functionally equivalent role of a person holding such titles notwithstanding
a lack of such title or any other title), each person who controls such indemnified person (within the meaning of Section 15 of the Securities
Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other
persons with a functionally equivalent role of a person holding such titles notwithstanding a lack of such title or any other title)
of such controlling person, from and against all losses, liabilities, claims, damages, costs, fees and expenses whatsoever (including,
but not limited to, any and all expenses incurred in investigating, preparing or defending against any litigation commenced or threatened)
based upon or arising out of the Purchaser’s actual or alleged false acknowledgment, representation or warranty, or misrepresentation
or omission to state a material fact, or breach by the Purchaser of any covenant or agreement made by the Purchaser, contained herein
or in any other document delivered by the Purchaser in connection with this Agreement. The liability of the Purchaser under this paragraph
shall not exceed the aggregate Purchase Price paid by the Purchaser for Shares hereunder.

 

6.4
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered
via facsimile (provided the sender receives a machine-generated confirmation of successful transmission) at the facsimile number specified
in this Section 6.4 prior to 5:00 P.M., New York City time, on a Trading Day, (b) the next Trading Day after the date of transmission,
if such notice or communication is delivered via facsimile at the facsimile number specified in this Section 6.4 on a day that
is not a Trading Day or later than 5:00 P.M., New York City time, on any Trading Day, (c) the Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service with next day delivery specified, or (d) upon actual receipt by the party
to whom such notice is required to be given. The address for such notices and communications shall be as follows:

 

	 	If
    to the Company: 	Blue
    Star Foods Corp.
	 	    	3000
    NW 109th Avenue
	 	   	Miami,
Florida 33172
	 	    	Attention:
    John Keeler
	 	   	Executive
Chairman and CEO
	 	 	 
	 	With
    a copy to:  	The
    Crone Law Group, P.C. 
	 	(which
    shall not 	500
Fifth Avenue, Suite 938
	 	constitute
notice)  	New
York, NY 10110

 

If
to the Purchaser: To the address set forth under such Purchaser’s name on the signature page hereof; or such other address as may
be designated in writing hereafter, in the same manner, by such person.

 

    	18

     

    

 

6.5
Amendments; Waivers; No Additional Consideration. No provision of this Agreement may be waived, modified, supplemented or amended
except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers of at least 66 2/3% of the Securities
still held by Purchasers or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought. No waiver of
any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the
future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay
or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right. No consideration shall
be offered or paid to any Purchaser to amend or consent to a waiver or modification of any provision of this Agreement unless the same
consideration is also offered to all Purchasers who then hold the Securities.

 

6.6
Construction. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the
parties to express their mutual intent, and no rules of strict construction will be applied against any party. This Agreement shall be
construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by
virtue of the authorship of any provisions of any of the Transaction Documents.

 

6.7
Successors and Assigns. The provisions of this Agreement shall inure to the benefit of and be binding upon the parties and their
successors and permitted assigns. This Agreement, or any rights or obligations hereunder, may not be assigned by the Company without
the prior written consent of each Purchaser. Any Purchaser may assign its rights hereunder in whole or in part to any person to whom
such Purchaser assigns or transfers any securities in compliance with the Transaction Documents and applicable law, provided such transferee
shall agree in writing to be bound, with respect to the transferred securities, by the terms and conditions of this Agreement that apply
to the “Purchasers”.

 

6.8
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

6.9
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be
governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all Proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective Affiliates,
employees or agents) shall be commenced exclusively in the New York Courts. Each party hereto hereby irrevocably submits to the exclusive
jurisdiction of the New York Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives,
and agrees not to assert in any Proceeding, any claim that it is not personally subject to the jurisdiction of any such New York Court,
or that such Proceeding has been commenced in an improper or inconvenient forum. Each party hereto hereby irrevocably waives personal
service of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or certified
mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall
be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES,
TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING
TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

    	19

     

    

 

6.10
Survival. Subject to applicable statute of limitations, the representations, warranties, agreements and covenants contained herein
shall survive the Closing and the delivery of the Shares and the Warrants.

 

6.11
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party,
it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile signature page were an
original thereof.

 

6.12
Severability. If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such
substitute provision in this Agreement.

 

6.13
Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) the Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and
the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw,
in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part
without prejudice to its future actions and rights.

 

6.14
Replacement of Securities. If the Securities are issued in certificated form, then any certificate or instrument evidencing the
Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and
upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence
reasonably satisfactory to the Company and its transfer agent of such loss, theft or destruction and the execution by the holder thereof
of a customary lost certificate affidavit of that fact and an agreement to indemnify and hold harmless the Company and the transfer agent
for any losses in connection therewith or, if required by the transfer agent, a bond in such form and amount as is required by the transfer
agent. The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated
with the issuance of such replacement securities. If a replacement certificate or instrument evidencing any securities is requested due
to a mutilation thereof, the Company may require delivery of such mutilated certificate or instrument as a condition precedent to any
issuance of a replacement.

 

6.15
Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing
sentence and hereby agree to waive in any action for specific performance of any such obligation (other than in connection with any action
for a temporary restraining order) the defense that a remedy at law would be adequate.

 

6.16
Payment Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.

 

    	20

     

    

 

6.17
Adjustments in Share Numbers and Prices. In the event of any stock split, subdivision, dividend or distribution payable in shares
of Common Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares
of Common Stock), combination or other similar recapitalization or event occurring after the date hereof and prior to the Closing, each
reference in any Transaction Document to a number of shares or a price per share shall be deemed to be amended to appropriately account
for such event.

 

6.18
Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
of the obligations of any other Purchaser under any Transaction Document. The decision of each Purchaser to purchase Securities pursuant
to the Transaction Documents has been made by such Purchaser independently of any other Purchaser and independently of any information,
materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition
(financial or otherwise) or prospects of the Company or any Subsidiary which may have been made or given by any other Purchaser or by
any agent or employee of any other Purchaser, and no Purchaser and any of its agents or employees shall have any liability to any other
Purchaser (or any other person) relating to or arising from any such information, materials, statement or opinions. Nothing contained
herein or in any Transaction Document, and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers
as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any
way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection with making its investment hereunder
and that no Purchaser will be acting as agent of such Purchaser in connection with monitoring its investment in the securities or enforcing
its rights under the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights, including
without limitation the rights arising out of any of the Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal
counsel in its review and negotiation of the Transaction Documents.

 

6.19
Termination. This Agreement may be terminated and the sale and purchase of the Securities abandoned at any time prior to the Closing
by either the Company or any Purchaser (with respect to itself only) upon written notice to the other, if the Closing has not been consummated
on or prior to 5:00 P.M., New York City time, on June 30, 2021 (the “Termination Date”); provided, however, that the right
to terminate this Agreement under this Section 6.19 shall not be available to any person whose failure to comply with its obligations
under this Agreement has been the cause of or resulted in the failure of the Closing to occur on or before such time. Nothing in this
Section 6.19 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions
of this Agreement or the other Transaction Documents or to impair the right of any party to compel specific performance by any other
party of its obligations under this Agreement or the other Transaction Documents. In the event of a termination pursuant to this Section
6.19, the Company shall promptly notify all non-terminating Purchasers. Upon a termination in accordance with this Section 6.19,
the Company and the terminating Purchaser(s) shall not have any further obligation or liability (including arising from such termination)
to the other, and no Purchaser will have any liability to any other Purchaser under the Transaction Documents as a result therefrom.

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]

 

    	21

     

    

 

IN
WITNESS WHEREOF, the Company has duly executed this Agreement as of the date first set forth above.

 

	 	BLUE
    STAR FOODS CORP.
	 	 	 
	 	By:
    	 
	 	Name:
    	John
    R. Keeler
	 	Title:
    	Executive
    Chairman and Chief Executive Officer 

 

[Signature
Page to Subscription Agreement]

 

    	22

     

    

 

How
to subscribe for Shares in the private offering of Blue Star Foods Corp.

 

	1.	Complete,
    Sign and Date the Omnibus Signature Page for the Subscription Agreement.
	 	 
	2.	Initial
    the Accredited Investor Certification in the appropriate place or places.
	 	 
	3.	Email
    your completed and signed Subscription Agreement and the Accredited Investor Certification to Eric C. Mendelson, Esq. at emendelson@cronelawgroup.com,
    copied to Eleanor Osmanoff, Esq. eosmanoff@cronelawgroup.com.
	 	 
	4.	If
    you are paying the Purchase Price by check, a certified or other bank check for the exact dollar amount of the Purchase Price
    for the number of Shares you are purchasing should be made payable to the order of Crone Law Group, P.C., as Escrow Agent for
    Blue Star Foods Corp., Acct. # 157802262 and should be sent to the Escrow Agent, at the following address:

 

The
Crone Law Group, PC

Attention:
Courtney Truesdell

300
South Point Drive, #1206, Miami Beach, FL 33139

 

Checks
take up to 5 business days to clear.

 

If
you are paying the Purchase Price by wire transfer, you should send a wire transfer for the exact dollar amount of the Purchase
Price for the number of Shares you are purchasing according to the following instructions:

 

	Bank:	JPMorgan
    Chase Bank, N.A
	 	1333
    4th Street, Santa Monica CA 90401
	ABA
    Routing #:	322271627
	SWIFT
    CODE:	CHASUS33
	Account
    Name:	Crone
    Law Group, P.C. IOLTA Trust Account
	Account
    #:	157802262
	Reference:	“Blue
    Star Foods Corp. [NAME]”
	Escrow
    Account Contact:	Russell
    Davidson – (415) 203-5116

 

Thank
you for your interest.

 

    	 

     

    

 

Blue
Star Foods Corp.

OMNIBUS
SIGNATURE PAGE TO

SUBSCRIPTION
AGREEMENT AND ESCROW AGREEMENT

 

The
undersigned, desiring to: (i) enter into the Subscription Agreement, dated as of ____________ ___,1 2021 (the “Subscription
Agreement”), between the undersigned, Blue Star Foods Corp., a Delaware corporation (the “Company”),
and the Purchaser, in or substantially in the form furnished to the undersigned, (ii) enter into the Escrow Agreement (the “Escrow
Agreement”), among the undersigned, the Company and the other parties thereto, in or substantially in the form furnished to the
undersigned, and (iii) purchase the Shares of the Company as set forth in the Subscription Agreement, hereby agrees to purchase such
Shares from the Company as set forth below and further agrees to be bound in all respects by the terms and conditions thereof. The undersigned
specifically acknowledges having read the representations section in the Subscription Agreement entitled “Representations and Warranties
of the Purchaser” and hereby represents that the statements contained therein are complete and accurate with respect to the undersigned
as a Purchaser.

 

IN
WITNESS WHEREOF, the Purchaser hereby executes this Agreement.

 

Dated:
________________________, 2021

 

	 	______________	X	$2.00___________	=	$___________________
	 	Number
    of Shares 	 	Purchase
    Price per Share	 	Total
    Purchase Price
	 	 	 	 	 	 
	 	______________	 	 	 	 
	 	Number
    of Warrants	 	 	 	 

 

	PURCHASER
    (individual)	 	PURCHASER (entity)
	 	 	 	 
	 	 	 
	Signature	 	Name of Entity
	 	 	 	                     
		 	By:
    	 

	Print
    Name	 	Signature

	 	 	 

	 	 	Print
    Name: 	 

	Signature
    (if Joint Tenants or Tenants in Common)	 	Title:
    	 

	 	 	 
	Address
    of Principal Residence:	 	Address
    of Executive Offices:
	 	 	 
	 	 	 
	 	 	 
	Social
    Security Number(s):	 	IRS
    Tax Identification Number:
	 	 	 
	 	 	 
	Telephone
    Number:	 	Telephone
    Number:
	 	 	 
	 	 	 
	Facsimile
    Number:	 	Facsimile
    Number:
	 	 	 
	 	 	 
	E-mail
    Address:	 	E-mail
    Address:
	 	 	 

 

 

1 Will reflect the Closing
Date. Not to be completed by Purchaser. 

 

    	 

     

    

 

Blue
Star Foods Corp.

 

ACCREDITED
INVESTOR CERTIFICATION

 

For
Individual Investors Only

(all
Individual Investors must INITIAL where appropriate):

 

	Initial
    _______	I
    have a net worth of at least $1,000,000 either individually or through aggregating my individual holdings and those in which I have
    a joint, community property or other similar shared ownership interest with my spouse. (For purposes of calculating your net
    worth under this paragraph, (a) your primary residence shall not be included as an asset; (b) indebtedness secured by your
    primary residence, up to the estimated fair market value of your primary residence at the time of your purchase of the Shares, shall
    not be included as a liability (except that if the amount of such indebtedness outstanding at the time of your purchase of the Shares
    exceeds the amount outstanding sixty (60) days before such time, other than as a result of the acquisition of your primary residence,
    the amount of such excess shall be included as a liability); and (c) indebtedness that is secured by your primary residence in excess
    of the estimated fair market value of your primary residence at the time of your purchase of the Shares shall be included as a liability.)
	 	 
	Initial
    _______	I
    have had an annual gross income for the past two (2) years of at least $200,000 (or $300,000 jointly with my spouse) and expect my
    income (or joint income, as appropriate) to reach the same level in the current year.
	 	 
	Initial
    _______	I
    am a director or executive officer of the Company
	 	 
	For Non-Individual Investors (Entities)
	(all Non-Individual Investors must INITIAL where appropriate):
	 	 
	Initial
    _______	The
    investor certifies that it is a partnership, corporation, limited liability company or business trust that is 100% owned by persons
    who meet at least one of the criteria for Individual Investors set forth above (in which case each such person must complete the
    Accreditor Investor Certification for Individuals above as well the remainder of this questionnaire).
	 	 
	Initial
    _______	The
    investor certifies that it is a partnership, corporation, limited liability company or business trust that has total assets of at
    least $5,000,000 and was not formed for the purpose of investing the Company.
	 	 
	Initial
    _______	The
    investor certifies that it is an employee benefit plan whose investment decision is made by a plan fiduciary (as defined in Section
    3(21) of the Employee Retirement Income Security Act of 1974) that is a bank, savings and loan association, insurance company or
    registered investment advisor.
	 	 
	Initial
    _______	The
    investor certifies that it is an employee benefit plan whose total assets exceed $5,000,000 as of the date of this Agreement.
	 	 
	Initial
    _______	The
    undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are made solely by persons who
    meet at least one of the criteria for Individual Investors.
	 	 
	Initial
    _______	The
    investor certifies that it is a U.S. bank as defined in Section 3(a)(2) of the Securities Act, or any U.S. savings and loan association
    or other similar U.S. institution as defined in Section 3(a)(5) of the Securities Act acting in its individual or fiduciary capacity.

 

    	 

     

    

 

	Initial
    _______	The
    undersigned certifies that it is a broker-dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934.
	 	 
	Initial
    _______	The
    investor certifies that it is an organization described in Section 501(c)(3) of the Internal Revenue Code with total assets exceeding
    US$5,000,000 and not formed for the specific purpose of investing in the Company.
	 	 
	Initial
    _______	The
    investor certifies that it is a trust with total assets of at least $5,000,000, not formed for the specific purpose of investing
    in the Company, and whose purchase is directed by a person with such knowledge and experience in financial and business matters that
    such person is capable of evaluating the merits and risks of the prospective investment.
	 	 
	Initial
    _______	The
    investor certifies that it is a plan established and maintained by a state or its political subdivisions, or any agency or instrumentality
    thereof, for the benefit of its employees, and which has total assets in excess of $5,000,000.
	 	 
	Initial
    _______	The
    investor certifies that it is an insurance company as defined in Section 2(13) of the Securities Act of 1933.
	 	 
	Initial
    _______	The
    investor certifies that it is an investment company registered under the Investment Company Act of 1940 or a business development
    company as defined in Section 2(a)(48) of that Act.
	 	 
	Initial
    _______	The
    investor certifies that it is a Small Business Investment Company licensed by the U.S. Small Business Administration under Section
    301(c) or (d) of the Small Business Investment Act of 1958.
	 	 
	Initial
    _______	The
    investor certifies that it is a private business development company as defined in Section 202(a)(22) of the Investment Advisers
    Act of 1940.

 

    	 

     

    

 

EXHIBIT
A

 

Form
of Warrant

 

    	 

     

    

 

EXHIBIT
B

 

Form
of Escrow AgreementEX-4.1

 Exhibit 4.1 

SIGHT SCIENCES, INC. 

THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

Dated as of November 23, 2020 

 TABLE OF CONTENTS 

 

									
	 	 	 	  	 	  	Page	 
	 1.
	 	 Registration Rights
	  	 	1	 
				
		 	1.1	  	 Definitions. For purposes of this Agreement:
	  	 	1	 
		 	1.2	  	 Request for Registration.
	  	 	3	 
		 	1.3	  	 Company Registration.
	  	 	5	 
		 	1.4	  	 Obligations of the Company
	  	 	6	 
		 	1.5	  	 Information From Holder
	  	 	8	 
		 	1.6	  	 Expenses of Registration
	  	 	8	 
		 	1.7	  	 Delay of Registration
	  	 	8	 
		 	1.8	  	 Indemnification
	  	 	8	 
		 	1.9	  	 Reports Under the 1934 Act
	  	 	11	 
		 	1.10	  	 Assignment of Registration Rights
	  	 	11	 
		 	1.11	  	 Limitations on Subsequent Registration Rights
	  	 	11	 
		 	1.12	  	 Termination of Registration Rights
	  	 	12	 
			
	 2.
	 	 “Market Stand-Off” Agreement
	  	 	12	 
			
	 3.
	 	 Covenants of the Company
	  	 	13	 
				
		 	3.1	  	 Delivery of Financial Statements
	  	 	13	 
		 	3.2	  	 Inspection
	  	 	14	 
		 	3.3	  	 Board Observer Right
	  	 	14	 
		 	3.4	  	 Right of First Offer
	  	 	14	 
		 	3.5	  	 Insurance
	  	 	17	 
		 	3.6	  	 Employee Stock
	  	 	18	 
		 	3.7	  	 Employees and Consultants
	  	 	18	 
		 	3.8	  	 Board Committees
	  	 	18	 
		 	3.9	  	 Successor Indemnification
	  	 	18	 
		 	3.10	  	 FCPA
	  	 	18	 
		 	3.11	  	 Termination of Certain Covenants
	  	 	19	 
			
	 4.
	 	 Miscellaneous.
	  	 	19	 
				
		 	4.1	  	 Successors and Assigns
	  	 	19	 
		 	4.2	  	 Governing Law; Venue
	  	 	19	 
		 	4.3	  	 Specific Enforcement
	  	 	19	 
		 	4.4	  	 Counterparts
	  	 	19	 
		 	4.5	  	 Titles and Subtitles
	  	 	19	 
		 	4.6	  	 Notices
	  	 	20	 
		 	4.7	  	 Expenses
	  	 	20	 
		 	4.8	  	 Amendments and Waivers
	  	 	20	 
		 	4.9	  	 Additional Investors
	  	 	20	 
		 	4.10	  	 Severability
	  	 	20	 
		 	4.11	  	 Aggregation of Stock
	  	 	21	 
		 	4.12	  	 Termination of Prior Agreement
	  	 	21	 
		 	4.13	  	 Entire Agreement
	  	 	21	 

  
 i 

 SIGHT SCIENCES, INC. 

THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of November 23, 2020 by and
among Sight Sciences, Inc., a Delaware corporation (the “Company”) and the investors listed on Schedule A hereto (each an “Investor” and collectively the “Investors”). 

RECITALS 
 Certain of the
Investors (the “Prior Investors”) holding shares of Series A Preferred Stock of the Company (the “Series A Preferred Stock”), shares of Series B Preferred Stock of the Company (the “Series B Preferred Stock”), shares of
Series C Preferred Stock of the Company (the “Series C Preferred Stock”), shares of Series D Preferred Stock of the Company (the “Series D Preferred Stock”), shares of Series E Preferred Stock of the Company (the “Series E
Preferred Stock”), and/or shares of Common Stock issued upon conversion thereof, are parties to that certain Second Amended and Restated Investors’ Rights Agreement dated as of March 17, 2020 by and among the Company and such Prior
Investors (the “Prior Agreement”) and are the holders of a majority of the Registrable Securities (as defined therein) subject to or enjoying the rights under the Prior Agreement. 

Certain of the Investors and the Company are parties to that certain Series F Preferred Stock Purchase Agreement dated as of the date hereof
(the “Series F Purchase Agreement”) relating to the issue and sale of shares of Series F Preferred Stock of the Company (the “Series F Preferred Stock,” and together with the Series A Preferred Stock, Series B Preferred Stock,
Series C Preferred Stock, Series D Preferred Stock, and Series E Preferred Stock, the “Preferred Stock”). 
 The obligations of
the Company and the Investors under the Series F Purchase Agreement are conditioned, among other things, upon the execution and delivery of this Agreement by the Investors and the Company. 

NOW, THEREFORE, in consideration of the mutual premises and covenants set forth herein, the parties hereto agree that the Prior Agreement is
hereby amended and restated in its entirety to read as follows: 
 1.    Registration Rights. The Company
covenants and agrees as follows: 
 1.1    Definitions. For purposes of this Agreement: 

(a)    The term “1934 Act” means the Securities Exchange Act of 1934, as amended. 

(b)    The term “Act” means the Securities Act of 1933, as amended. 

(c)    The term “Affiliate” means, with respect to any specified person, any other person who or which,
directly or indirectly, controls, is controlled by, or is under common control with such specified person, including, without limitation, any general partner, 

 
officer, director or manager of such person and any venture capital fund, registered investment company or other investment fund now or hereafter existing that is controlled by one or more
general partners or managing members or investment advisor of, or shares the same management company or investment advisor (or member thereof) with, such person. Notwithstanding anything to the contrary contained herein, (i) Allegro Investors
LLC and Allegro Investment Fund, L.P. shall be deemed an Affiliate of each other, (ii) D1 Master Holdco I LLC, D1 Master Holdco II LLC, D1 Master Holdco III LLC and D1 Capital Partners Master LP shall all be deemed Affiliates of each other, and
(iii) (a) each Janus Investor shall be deemed to be an “Affiliate” of each other Janus Investor, and (b) an entity that is an “Affiliate” of a Janus Investor (other than pursuant to the foregoing subpart (a)) shall not
be deemed to be an “Affiliate” of any other Janus Investor unless such entity is a Janus Investor (and, for the avoidance of doubt, an “Affiliate” of such entity shall not be deemed an “Affiliate” of any Janus Investor
solely by virtue of being an “Affiliate” of such entity). 
 (d)    The term “D1” means D1 Master
Holdco I LLC, together with its Affiliates. 
 (e)    The term “Free Writing Prospectus” means a free-writing
prospectus, as defined in Rule 405. 
 (f)    The term “Form S-3”
means such form under the Act as in effect on the date hereof or any registration form under the Act subsequently adopted by the SEC that permits inclusion or incorporation of substantial information by reference to other documents filed by the
Company with the SEC. 
 (g)    The term “GAAP” means generally accepted accounting principles for financial
reporting in the United States as in effect from time to time applied consistently throughout the periods involved. 

(h)    The term “Holder” means any person owning or having the right to acquire Registrable Securities or any
assignee thereof in accordance with Section 1.10 hereof. 
 (i)    The term “Initial Offering” means the
Company’s first firm commitment underwritten public offering of its Common Stock under the Act. 
 (j)    The term
“Janus Investors” shall mean Investors, or permitted transferees of Registrable Securities held by Janus Investors, that are advisory or subadvisory clients of Janus Capital Management LLC, including, but not limited to, Janus Henderson
Venture Fund and Janus Henderson Capital Funds plc -Janus Henderson US Venture Fund.. 
 (k)    The terms
“register,” “registered,” and “registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Act, and the declaration or ordering of
effectiveness of such registration statement or document. 
 (l)    The term “Registrable Securities” means
(i) the Common Stock issuable or issued upon conversion of the Preferred Stock, and (ii) any Common Stock of the 

  
 2 

 
Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange for, or
in replacement of, the shares referenced in (i) above, excluding in all cases, however, any Registrable Securities sold by a person in a transaction in which his rights under this Section 1 are not assigned. 

(m)    The number of shares of “Registrable Securities” outstanding shall be determined by the number of shares
of Common Stock outstanding that are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible securities that are, Registrable Securities. 

(n)    The term “Restated Certificate” shall mean the Company’s Amended and Restated Certificate of
Incorporation, as amended and/or restated from time to time. 
 (o)    The term “Rule 144” shall mean Rule
144 under the Act. 
 (p)    The term “Rule 145” shall mean Rule 145 under the Act. 

(q)    The term “SEC” shall mean the Securities and Exchange 

(r)    The term “Specified Investor” shall mean D1. 

Commission. 

1.2    Request for Registration. 

(a)    Subject to the conditions of this Section 1.2, if the Company shall receive at any time after the earlier of
(i) five (5) years after the date of this Agreement, and (ii) six (6) months after the effective date of the Initial Offering, a written request from the Holders of at least a majority of the Registrable Securities outstanding (for
purposes of this Section 1.2, the “Initiating Holders”) that the Company file a registration statement under the Act covering the registration of Registrable Securities with an anticipated aggregate offering price of at least
$20,000,000, then the Company shall, within twenty (20) days of the receipt thereof, give written notice of such request to all Holders, and subject to the limitations of this Section 1.2, use its reasonable best efforts to, as soon as
practicable, file a registration statement under the Act with respect to all of the Registrable Securities that the Holders request to be registered in a written request received by the Company within twenty (20) days of the mailing of the
Company’s notice pursuant to this Section 1.2(a), and use reasonable best efforts to cause such registration statement to be declared effective by the SEC as soon as practicable. 

(b)    If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an
underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 1.2 and the Company shall include such information in the written notice referred to in Section 1.2(a). In such event the right of any
Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise
mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in
customary form with the 

  
 3 

 
underwriter or underwriters selected for such underwriting by the Company (which underwriter or underwriters shall be reasonably acceptable to a majority in interest of the Initiating Holders).
Notwithstanding any other provision of this Section 1.2, if the underwriter advises the Company that marketing factors require a limitation on the number of securities underwritten (including Registrable Securities), then the Company shall so
advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares that may be included in the underwriting shall be allocated to the Holders of such Registrable Securities pro rata based on
the number of Registrable Securities held by all such Holders (including the Initiating Holders). In no event shall any Registrable Securities be excluded from such underwriting unless all other securities are first excluded. Any Registrable
Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration. 

(c)    Notwithstanding the foregoing, the Company shall not be required to effect a registration pursuant to this
Section 1.2: 
 (i)    in any particular jurisdiction in which the Company would be required to execute a general
consent to service of process in effecting such registration, unless the Company is already subject to service in such jurisdiction and except as may be required under the Act; or 

(ii)    after the Company has effected two (2) registrations pursuant to this Section 1.2, and such
registrations have been declared or ordered effective; provided, however, that a registration shall not be considered “effected” if, as a result of the underwriter’s right in Section 1.2(b) to limit the number of
securities underwritten, fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually included; or 

(iii)    during the period starting with the date of the filing of and ending on a date one hundred eighty
(180) days following the effective date of a Company-initiated registration subject to Section 1.3 below, provided that the Company is actively employing in good faith reasonable best efforts to cause such registration statement to
become effective; or 
 (iv)    if the Company shall furnish to Holders requesting a registration statement pursuant to
this Section 1.2 a certificate signed by the Company’s Chief Executive Officer or Chairman of the Board stating (A) that the Company intends to file a registration statement for its Initial Offering within one hundred twenty
(120) days following the date of the initial request for registration made by the Initiating Holders pursuant to this Section 1.2 or (B) that in the good faith judgment of the Board of Directors of the Company, it would be seriously
detrimental to the Company and its stockholders for such registration statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than one hundred twenty (120) days after
receipt of the request of the Initiating Holders, provided that such right shall be exercised by the Company not more than once in any twelve (12)-month period and provided, further, that the Company shall not register any
securities for the account of itself or any other stockholder during such one hundred twenty (120) day period (other than a registration relating solely to the sale of securities of participants in a Company stock plan, a registration relating
to a corporate reorganization or transaction under Rule 145, a registration on any form that does not include substantially the same information as would be 

  
 4 

 
required to be included in a registration statement covering the sale of the Registrable Securities, or a registration in which the only Common Stock being registered is Common Stock issuable
upon conversion of debt securities that are also being registered). 
 1.3    Company Registration. 

(a)    If (but without any obligation to do so) the Company proposes to register (including for this purpose a
registration effected by the Company for stockholders other than the Holders that has been expressly approved by the Holders pursuant to Section 1.11) any of its stock or other securities under the Act in connection with the public offering of
such securities (other than a registration relating solely to the sale of securities of participants in a Company stock plan, a registration relating to a corporate reorganization or transaction under Rule 145, a registration on any form that does
not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities, a registration relating to the Initial Offering, or a registration in which the only
Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of
each Holder given within twenty (20) days after mailing of such notice by the Company in accordance with Section 1.3(c), the Company shall, subject to the provisions of Section 1.3(c), use reasonable best efforts to cause to be
registered under the Act all of the Registrable Securities that each such Holder requests to be registered. 

(b)    Right to Terminate Registration. The Company shall have the right to terminate or withdraw any registration
initiated by it under this Section 1.3 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. The expenses of such withdrawn registration shall be borne by the Company
in accordance with Section 1.6 hereof. 
 (c)    Underwriting Requirements. In connection with any offering
involving an underwriting of shares of the Company’s capital stock, the Company shall not be required under this Section 1.3 to include any of the Holders’ securities in such underwriting unless they accept the terms of the
underwriting as agreed upon between the Company and the underwriters selected by the Company (or by other persons entitled to select the underwriters) and enter into an underwriting agreement in customary form with such underwriters, and then only
in such quantity as the underwriters determine in their sole discretion will not jeopardize the success of the offering by the Company. If the total amount of securities, including Registrable Securities, requested by stockholders to be included in
such offering exceeds the amount of securities sold other than by the Company that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only
that number of such securities, including Registrable Securities, that the underwriters determine in their sole discretion will not jeopardize the success of the offering. The Company shall not, without the prior written consent of the holders of at
least a majority of the Registrable Securities then held by the Investors exclude any Registrable Securities from such offering unless all other stockholders’ securities have been first excluded. In the event that the underwriters determine
that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be apportioned 

  
 5 

 
first, to the Company; second, to the Investors on a pro rata basis based on the total number of Registrable Securities held by such Investors; and third, to any stockholder of the Company (other
than a Holder) on a pro rata basis so long as the number of Registrable Securities held by the Holders is not reduced. Notwithstanding the foregoing, in no event shall the amount of securities of the selling Investors included in the offering
be reduced below thirty percent (30%) of the total amount of securities included in such offering, unless such offering is the Initial Offering, in which case the selling Holders may be excluded if the underwriters make the determination described
above and no other stockholder’s securities are included in such offering. For purposes of the preceding sentence concerning apportionment, for any selling stockholder that is a Holder of Registrable Securities and that is a venture capital
fund, partnership or corporation, the affiliated venture capital funds, partners, retired partners and stockholders of such Holder, or the estates and family members of any such partners and retired partners and any trusts for the benefit of any of
the foregoing persons shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate amount of Registrable Securities owned by all such related
entities and individuals. 
 1.4    Obligations of the Company. Whenever required under this Section 1 to
effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a)    prepare and file with the SEC a registration statement with respect to such Registrable Securities and use
reasonable best efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up
to ninety (90) days or, if earlier, until the distribution contemplated in the Registration Statement has been completed; 

(b)    prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus
used in connection with such registration statement as may be necessary to comply with the provisions of the Act with respect to the disposition of all securities covered by such registration statement; 

(c)    furnish to the Holders such number of copies of a prospectus, including a preliminary prospectus and any Free
Writing Prospectus, in conformity with the requirements of the Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them; 

(d)    use reasonable best efforts to register and qualify the securities covered by such registration statement under
such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to
file a general consent to service of process in any such states or jurisdictions; 
 (e)    in the event of any
underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering; 

  
 6 

 (f)    notify each Holder of Registrable Securities covered by such
registration statement at any time when a prospectus or Free Writing Prospectus (to the extent prepared by or on behalf of the Company) relating thereto is required to be delivered under the Act of the happening of any event as a result of which the
prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the
light of the circumstances then existing, and, at the request of any such Holder, the Company will, as soon as reasonably practicable, file and furnish to all such Holders a supplement or amendment to such prospectus or Free Writing Prospectus (to
the extent prepared by or on behalf of the Company) so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus will not contain an untrue statement of a material fact or omit to state any fact necessary to
make the statements therein not misleading in light of the circumstances under which they were made; 
 (g)    cause
all such Registrable Securities registered pursuant to this Section 1 to be listed on a national exchange or trading system and on each securities exchange and trading system on which similar securities issued by the Company are then listed;

 (h)    provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement
and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; and 

(i)    use reasonable best efforts to furnish, at the request of any Holder requesting registration of Registrable
Securities pursuant to this Section 1, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, if such securities are being sold through
underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, (i) an opinion, dated as of such date, of the counsel representing the
Company for the purposes of such registration, and (ii) a “comfort” letter, dated as of such date, from the independent certified public accountants of the Company, in each case in form and substance as is customarily given to
underwriters in an underwritten public offering and reasonably satisfactory to a majority in interest of the Holders requesting registration, addressed to the underwriters and to the Holders requesting registration of Registrable Securities. 

Notwithstanding the provisions of this Section 1, the Company shall be entitled to postpone or suspend, for a reasonable period of time,
the filing, effectiveness or use of, or trading under, any registration statement if the Company shall determine that any such filing or the sale of any securities pursuant to such registration statement would in the good faith unanimous judgment of
the Board of Directors of the Company: 
 (i)    materially impede, delay or interfere with any material pending or
proposed financing, acquisition, corporate reorganization or other similar transaction involving the Company for which the Board of Directors of the Company has authorized negotiations; 

(ii)    materially adversely impair the consummation of any pending or proposed material offering or sale of any class of
securities by the Company; or 

  
 7 

 (iii)    require disclosure of material nonpublic information that, if
disclosed at such time, would be materially harmful to the interests of the Company and its stockholders; provided, however, that during any such period all executive officers and directors of the Company are also prohibited from
selling securities of the Company (or any security of any of the Company’s subsidiaries or affiliates). 
 In the event of the
suspension of effectiveness of any registration statement pursuant to this Section 1.4, the applicable time period during which such registration statement is to remain effective shall be extended by that number of days equal to the number of
days the effectiveness of such registration statement was suspended. 
 1.5    Information From Holder. It shall
be a condition precedent to the obligations of the Company to take any action pursuant to this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding
itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be reasonably required to effect the registration of such Holder’s Registrable Securities. 

1.6    Expenses of Registration. All expenses other than underwriting discounts and commissions incurred in
connection with registrations, filings or qualifications pursuant to Sections 1.2 and 1.3, including (without limitation) all registration, filing and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for
the Company and the reasonable fees and disbursements not to exceed $25,000 of one counsel for the selling Holders shall be borne by the Company. Notwithstanding the foregoing, the Company shall not be required to pay for any expenses of any
registration proceeding begun pursuant to Section 1.2 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all participating Holders
shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless, in the case of a registration requested under Section 1.2, the Holders of at least a majority of
the Registrable Securities then held by the Investors agree to forfeit their right to one demand registration pursuant to Section 1.2 and provided, however, that if at the time of such withdrawal, the Holders have learned of a
material adverse change in the condition, business or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such material adverse change, then
the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 1.2. 

1.7    Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or
otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 

1.8    Indemnification. In the event any Registrable Securities are included in a registration statement under this
Section 1: 
 (a)    To the extent permitted by law, the Company will indemnify and hold harmless each Holder, its
Affiliates and their respective partners, members, managers, officers, directors, stockholders, legal counsel and accountants, any underwriter (as defined in 

  
 8 

 
the Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Act or the 1934 Act, against any losses, claims, damages or liabilities (joint
or several) to which they may become subject under the Act, the 1934 Act, any state securities laws or any rule or regulation promulgated under the Act, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise
out of or are based upon any of the following statements, omissions or violations (collectively a “Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any
preliminary prospectus, final prospectus or Free Writing Prospectus contained therein or any amendments or supplements thereto, any issuer information (as defined in Rule 433 of the Act) filed or required to be filed pursuant to Rule 433(d) under
the Act or any other document incident to such registration prepared by or on behalf of the Company or used or referred to by the Company, (ii) the omission or alleged omission to state in such registration statement a material fact required to
be stated therein, or necessary to make the statements therein not misleading or (iii) any violation or alleged violation by the Company of the Act, the 1934 Act, any state securities laws or any rule or regulation promulgated under the Act,
the 1934 Act or any state securities laws, and the Company will reimburse each such Holder, underwriter, controlling person or other aforementioned person for any legal or other expenses reasonably incurred by them in connection with investigating
or defending any such loss, claim, damage, liability or action as such expenses are incurred; provided, however, that the indemnity agreement contained in this subsection 1.8(a) shall not apply to amounts paid in settlement of any
such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case with respect to a specific Holder
for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation that occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such
registration by any such Holder, underwriter, controlling person or other aforementioned person. 
 (b)    To the
extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the
Company within the meaning of the Act, legal counsel and accountants for the Company, any underwriter, any other Holder selling securities in such registration statement and any controlling person of any such underwriter or other Holder, against any
losses, claims, damages or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Act, the 1934 Act, any state securities laws or any rule or regulation promulgated under the Act, the 1934 Act or any state
securities laws, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and
in conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will reimburse any person intended to be indemnified pursuant to this subsection 1.8(b) for any legal
or other expenses reasonably incurred by such person in connection with investigating or defending any such loss, claim, damage, liability or action as such expenses are incurred; provided, however, that the indemnity agreement
contained in this subsection 1.8(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder (which consent shall not be unreasonably
withheld), and provided that in no event shall any indemnity under this subsection 1.8(b), when aggregated with any contribution obligation under Section 1.8(d), exceed the net proceeds from the offering received by such Holder.

  
 9 

 (c)    Promptly after receipt by an indemnified party under this
Section 1.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying
party under this Section 1.8, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in and, to the extent the indemnifying party so desires, jointly with
any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be
represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying
party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of liability to the indemnified party under this Section 1.8 to the extent of such
prejudice, but the omission to so deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 1.8. 

(d)    If the indemnification provided for in this Section 1.8 is held by a court of competent jurisdiction to be
unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to herein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or
payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and the indemnified party on the other hand
in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense, as well as any other relevant equitable considerations; provided, however, that no contribution by any Holder, when
combined with any amounts paid by such Holder pursuant to Section 1.8(b) and any other contributions by such Holder, shall exceed the net proceeds from the offering received by such Holder. The relative fault of the indemnifying party and the
indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided, however, that no person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) will be entitled to contribution from any person who or which was not guilty of such fraudulent misrepresentation. 

(e)    Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in
the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

  
 10 

 (f)    The obligations of the Company and Holders under this
Section 1.8 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1 and otherwise. 

1.9    Reports Under the 1934 Act. With a view to making available to the Holders the benefits of Rule 144 and any
other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to:

 (a)    make and keep adequate current public information available, as those terms are understood and defined in
Rule 144, at all times after the effective date of the Initial Offering; 
 (b)    file with the SEC in a timely manner
all reports and other documents required of the Company under the Act and the 1934 Act; and 
 (c)    furnish to any
Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144 (at any time after ninety (90) days after the
effective date of the first registration statement filed by the Company), the Act and the 1934 Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant
to Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other
information as may be reasonably requested to avail any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration or pursuant to such form. 

1.10    Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities
pursuant to this Section 1 may be assigned (but only with all related obligations) by a Holder to a transferee or assignee of such securities that (i) is an Affiliate, subsidiary, parent, partner, limited partner, retired partner or
stockholder of a Holder, (ii) is a Holder’s family member or trust for the benefit of an individual Holder, or (iii) after such assignment or transfer, holds at least 100,000 shares of Registrable Securities (subject to appropriate
adjustment for stock splits, stock dividends, combinations or the like), provided: (a) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and
the securities with respect to which such registration rights are being assigned; (b) such transferee or assignee agrees in writing to be bound by and subject to the terms and conditions of this Agreement, including, without limitation, the
provisions of Section 2 below; and (c) such assignment shall be effective only if immediately following such transfer the further disposition of such securities by the transferee or assignee is restricted under the Act. 

1.11    Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall
not, without the prior written consent of the Investors holding a majority of the then outstanding Registrable Securities, enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder
or prospective holder (a) to include any of such securities in any registration filed under Section 1.2 or 1.3 hereof, 

  
 11 

 
unless under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not
reduce the amount of the Registrable Securities of the Holders that are included, (b) to demand registration of their securities or (c) to exercise other registration rights that are pari passu or senior to those granted to the Holders
hereunder. 
 1.12    Termination of Registration Rights. No Holder shall be entitled to exercise any right
provided for in this Section 1, and none of the shares of capital stock owned by such Holder shall be Registrable Securities, upon the earliest to occur of the following: (a) after five (5) years following the consummation of the
Initial Offering, (b) as to any Holder, such earlier time after the Initial Offering at which all Registrable Securities held by such Holder (together with any Affiliate of the Holder with whom such Holder must aggregate its sales under Rule
144) can be sold in any ninety (90) day period without registration in compliance with Rule 144 or (c) upon the consummation of a transaction or series of related transactions which are deemed to be a liquidation, dissolution or winding up
of the Company pursuant to the Restated Certificate. 
 2.    “Market
Stand-Off” Agreement. 
 2.1    Each Holder hereby agrees
that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the Company’s Initial Offering and ending on the date specified by the Company and the
managing underwriter (such period not to exceed one hundred eighty (l80) days plus such additional period as may reasonably be requested by the Company or such underwriter to accommodate regulatory restrictions on (i) the publication or other
distribution of research reports or (ii) analyst recommendations and opinions, including (without limitation) the restrictions set forth in FINRA Rule 2711(f)(4) or any similar successor rules) (i) lend, offer, pledge, sell, contract to
sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock held immediately prior to the effectiveness of the Registration Statement for such offering, or (ii) enter into any swap or other arrangement that transfers to another, in whole
or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash or otherwise. The
foregoing provisions of this Section 2.1 shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall only be applicable to the Holders if all officers, directors and greater than one percent (1%)
stockholders of the Company enter into similar agreements. The underwriters in connection with the Company’s Initial Offering are intended third party beneficiaries of this Section 2.1 and shall have the right, power and authority to
enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in the Company’s Initial Offering that are consistent with this
Section 2.1 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to
such agreements, based on the number of shares subject to such agreements. 

  
 12 

 In order to enforce the foregoing covenant, the Company may impose stop transfer
instructions with respect to the Registrable Securities of each Holder (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period. 

2.2    Each Holder agrees that a legend reading substantially as follows shall be placed on all certificates representing
all Registrable Securities of each Holder (and the shares or securities of every other person subject to the restriction contained in this Section 2): 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD OF UP TO 180 DAYS AFTER
THE EFFECTIVE DATE OF THE ISSUER’S REGISTRATION STATEMENT FILED UNDER THE ACT, AS AMENDED, AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL HOLDER OF THESE SECURITIES, A COPY OF WHICH MAY BE OBTAINED AT THE ISSUER’S
PRINCIPAL OFFICE. SUCH LOCK-UP PERIOD IS BINDING ON TRANSFEREES OF THESE SHARES. 

3.    Covenants of the Company. 

3.1    Delivery of Financial Statements and Other Information. The Company shall deliver to each Investor that
together with its Affiliates continues to hold at least 180,000 shares of Preferred Stock of the Company (as adjusted for stock splits, stock dividends, recapitalizations and the like): 

(a)    as soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal
year of the Company (or such later period approved by the Board of Directors), an income statement for such fiscal year, a balance sheet of the Company and statement of stockholders’ equity as of the end of such fiscal year, and a statement of
cash flows for such fiscal year, all such financial statements audited and certified by independent public accountants of regionally recognized standing selected by the Company; 

(b)    as soon as practicable, but in any event within forty-five (45) days after the end of each of the four
(4) quarters of each fiscal year of the Company, an unaudited income statement, statement of cash flows for such fiscal quarter and an unaudited balance sheet as of the end of such fiscal quarter, along with an up-to-date capitalization table of the Company; and 
 (c)    within thirty
(30) days prior to the beginning of each fiscal year, a budget and business plan for the next fiscal year, prepared on a monthly basis, including balance sheets, income statements and statements of cash flows for such months and, as soon as
prepared, any other budgets or revised budgets prepared by the Company and approved by the Company’s Board of Directors. 
 All income
statements, balance sheets, statements of stockholders’ equity and statements of cash flow delivered by the Company hereunder shall (1) be prepared in accordance with GAAP (except that interim financial statements may be subject to normal
recurring year-end adjustments, the effect of which will not, individually or in the aggregate, be material to the Company), (2) be correct and complete in all material respects, (3) be consistent in all
material respects with the 

  
 13 

 
books and records of the Company and (4) fairly present, in all material respects, the financial condition, results of operations, changes in stockholders’ equity and cash flows of the
Company as of the respective dates and for the periods indicated therein. 
 3.2    Inspection. The Company shall
permit each Investor that together with its Affiliates continues to hold at least 180,000 shares of Preferred Stock of the Company (as adjusted for stock splits, stock dividends, recapitalizations and the like), at such Investor’s expense, and
upon reasonable notice, during normal business hours, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such
reasonable times as may be reasonably requested by the Investor; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith
considers to be a trade secret or similar confidential information, and provided, further, that the Company may require the Investor to execute a confidentiality and nondisclosure agreement with restrictions that are reasonable under
the circumstances prior to any such visit and inspection. 
 3.3    Board Observer Right. For so long as D1
continues to hold at least twenty-five percent (25%) of the shares of Series E Preferred Stock and Series F Preferred Stock of the Company (as adjusted for stock splits, stock dividends, recapitalizations and the like) purchased by D1 pursuant to
the Series E Purchase Agreement and the Series F Purchase Agreement, the Company shall invite a representative of D1 to attend all meetings of the Board and any committees thereof in a nonvoting observer capacity and, in this respect, shall give (at
the same time and in the same manner that notice is given to other directors) such representative copies of all notices, minutes, consents, and other materials (financial or otherwise) that it provides to its directors. The initial observer shall be
James Rogers and such observer may be replaced by D1 from time to time. The Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at
such meeting, in the reasonable opinion of counsel, could adversely affect the attorney-client privilege between the Company and its counsel. D1 agrees, and any representative of D1 will agree, to hold in confidence and trust with respect to all
information provided to it or learned by it in connection with its rights under this Section 3.3, except that this shall in no way limit or restrict D1’s ability to disclose any such information to its partners, employees or affiliated
funds or to any banking regulatory authority or body, or to the extent otherwise required by law and any other regulatory process to which D1 is subject. 

3.4    Right of First Offer. Subject to the terms and conditions specified in this Section 3.4, the Company
hereby grants a right of first offer with respect to future private placement sales by the Company of its Shares (as hereinafter defined), as calculated pursuant to Section 3.4(b), (i) first, to D1 and the Janus Investors (together, the
“Qualifying Investors”), for so long as any shares of Series F Preferred Stock remain outstanding and the Qualifying Investors continue to collectively hold the majority of the then outstanding shares of Series E Preferred Stock and Series
F Preferred Stock, for up to an aggregate number of Shares equivalent to an aggregate total purchase price by all such Qualifying Investors of up to $70,000,000 (the “Maximum ROFO Amount of Shares”), and (ii) thereafter to all other
Investors that continue to hold shares of capital stock of the Company, for any remaining Shares not purchased by the Qualifying Investors under (i) above (the “Unpurchased Shares”). For purposes of this Section 3.4, an Investor
includes any partners and Affiliates of an Investor. An Investor shall be entitled to apportion the right of first 

  
 14 

 
offer hereby granted it among itself and its partners and Affiliates in such proportions as it deems appropriate, so long as such apportionment does not cause the loss of the exemption under
Section 4(a)(2) of the Act or any similar exemption under applicable state securities laws in connection with such sale of Shares by the Company. 

Each time the Company proposes in a private placement to offer any shares of, or securities convertible into or exchangeable or exercisable
for any shares of, any class of its capital stock (the “Shares”), the Company shall first make an offering of such Shares to each such Qualifying Investor in accordance with the following provisions: 

(a)    The Company shall deliver a notice in accordance with Section 4.6 (the “Notice”) to the Qualifying
Investors and all other Investors stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares to be offered, and (iii) the price, terms and conditions upon which it proposes to offer such Shares. 

(b)    By written notification received by the Company, within twenty (20) calendar days after receipt of the
Notice, (i) each Qualifying Investor may elect to purchase or obtain, at the price and on the terms specified in the Notice, up to that portion of the Maximum ROFO Amount of Shares that equals the proportion that the aggregate number of shares
of Common Stock issued and held, or issuable upon conversion of the Series E Preferred Stock and Series F Preferred Stock held as of the date hereof, by such Qualifying Investor bears to the total number of shares of Common Stock of the Company held
as of the date hereof by all Qualifying Investors (assuming full conversion and exercise of all outstanding convertible and exercisable securities); provided, however, if one Qualifying Investor decides not to purchase all the Shares available to it
under this subsection (i), then the other Qualifying Investor (“Fully Exercising QI”) shall be entitled to obtain that portion of the Shares for which the Qualifying Investors were entitled to subscribe but which were not subscribed for,
and (ii) any remaining Investor may elect to purchase or obtain, up to that portion of the Unpurchased Shares that equals the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion of the Preferred
Stock held as of the date hereof, by such Investor bears to the total number of shares of Common Stock of the Company outstanding as of the date hereof (assuming full conversion and exercise of all outstanding convertible and exercisable securities)
plus any shares of Common Stock reserved for issuance under any equity incentive plan approved by the Board of Directors as of the date hereof. The Company shall promptly, in writing, inform each Qualifying Investor and Investor which purchases all
the Shares available to it (“Fully-Exercising Investor”) of any other Investor’s failure to do likewise. During the ten (10) day period commencing after receipt of such information, each Fully-Exercising Investor shall be
entitled to obtain that portion of the Shares for which Investors were entitled to subscribe but which were not subscribed for by the Investors that is equal to the proportion that the number of shares of Common Stock issued and held, or issuable
upon conversion of Preferred Stock then held, by such Fully-Exercising Investor bears to the total number of shares of Common Stock issued and held, or issuable upon conversion of Preferred Stock then held, by all Fully-Exercising Investors who wish
to purchase some of the unsubscribed shares. 
 (c)    If all Shares that the Qualifying Investors and the Investors
are entitled to obtain pursuant to Section 3.4(b) are not elected to be obtained as provided in Section 3.4(b) hereof, the Company may, during the ninety (90) day period following the 

  
 15 

 
expiration of the period provided in Section 3.4(b) hereof, offer the remaining unsubscribed portion of such Shares to any person or persons at a price not less than, and upon terms no more
favorable to the offeree than those specified in the Notice. If the Company does not enter into an agreement for the sale of the Shares within such period, or if such agreement is not consummated within thirty (30) days of the execution
thereof, the right provided hereunder shall be deemed to be revived and such Shares shall not be offered unless first reoffered to the Investors in accordance herewith. 

(d)    Except with respect to D1’s and the Janus Investors’ rights under Section 3.4(f), the right of
first offer in this Section 3.4 shall not be applicable to: 
 (i)    the issuance of securities pursuant to a
split or subdivision of the outstanding shares of Common Stock or the determination of holders of Common Stock entitled to receive a dividend or other distribution payable in additional shares of Common Stock or other securities or rights
convertible into, or entitling the holder thereof to receive directly or indirectly, additional shares of Common Stock (hereinafter referred to as “Common Stock Equivalents”) without payment of any consideration by such holder for the
additional shares of Common Stock or the Common Stock Equivalents (including the additional shares of Common Stock issuable upon conversion or exercise thereof); 

(ii)    the issuance of shares of Common Stock or options therefor to employees, consultants, officers, directors or
strategic partners (if in transactions with primarily non-financing purposes) of the Company directly or pursuant to a stock option plan or restricted stock purchase plan approved by the Board of Directors of
the Company including at least the Series E/F Director (as defined in the Restated Certificate); 
 (iii)    the
issuance of shares of Common Stock (A) in a bona fide, firmly underwritten public offering under the Act before which or in connection with which all outstanding shares of Preferred Stock will be automatically converted to Common Stock, or
(B) upon exercise of warrants or rights granted to underwriters in connection with such a public offering; 

(iv)    the issuance of shares of Common Stock pursuant to the conversion or exercise of convertible or exercisable
securities outstanding as of the date hereof or subsequently issued pursuant to this Section 3.4; 
 (v)    the
issuance of shares of Common Stock in connection with a bona fide business acquisition of or by the Company, whether by merger, consolidation, sale of assets, sale or exchange of stock or otherwise, each as approved by the Board of Directors of the
Company, including at least the Series E/F Director; 
 (vi)    the issuance or sale of stock, warrants or other
securities or rights, for other than primarily equity financing purposes, as approved by the Board of Directors of the Company, including at least the Series E/F Director, to entities with which the Company has any of the following bona fide
business relationships: (1) joint venture, technology licensing or development activities, or (2) distribution, supply or manufacture of the Company’s products or services; 

  
 16 

 (vii)    the issuance or sale of stock, warrants or other securities or
rights in connection with commercial credit arrangements, equipment financings, commercial property lease transactions or similar transactions, each as approved by the Board of Directors of the Company, including at least the Series E/F Director; or

 (viii)    shares of Common Stock issued or issuable in connection with any transaction approved by the Board of
Directors of the Company, where such securities so issued are exempted from the right of first offer in this Section 3.4 by the affirmative vote of Investors holding at least a majority of the then outstanding Series F Preferred Stock held by
all Investors (voting together as a single class and not as separate series, and on an as-converted basis). 

In addition to the foregoing, the right of first offer in this Section 3.4 shall not be applicable with respect to any Investor and any
subsequent securities issuance, if (i) at the time of such subsequent securities issuance, the Investor is not an “accredited investor,” as that term is then defined in Rule 501(a) under the Act, and (ii) such subsequent
securities issuance is otherwise being offered only to accredited investors. 
 (e)    The right of first offer set
forth in this Section 3.4 may not be assigned or transferred, except that such right may be assigned (but only with all related obligations) by a Holder to a transferee or assignee of such rights that (i) is an Affiliate, subsidiary,
parent, partner, limited partner, retired partner or stockholder of a Holder, (ii) is a Holder’s family member or trust for the benefit of an individual Holder, or (iii) after such assignment or transfer, holds at least 100,000 shares
of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations or the like). 

(f)    Notwithstanding any provisions herein to the contrary, in the event of a Qualified IPO (as defined in the Restated
Certificate), the Company shall use its reasonable efforts, subject to the requirements of all applicable securities laws and regulations, to provide each of D1 and the Janus Investors with a right of first offer with respect to such shares of
Common Stock of the Company that either Holder desires to purchase, in each case, up to such number of shares equal to the greater of (i) $15,000,000 divided by the per share purchase price of the Company’s Common Stock in the Qualified IPO and
(ii) fifteen percent (15%) of the total number of shares of Common Stock to be sold in the Qualified IPO. If such right of first offer may not be granted to either Holder, then the Company shall, in good faith and upon the written request of
either Holder, consider the sale of an equivalent number of shares of the Company’s Common Stock to either Holder in a private placement transaction concurrent to the Qualified IPO. The Company may not reduce the amount of shares of Common
Stock that may be purchased by either D1 or the Janus Investors in the Qualified Financing or a concurrent private placement transaction, unless the same reduction is applied to both D1 and the Janus Investors. 

3.5    Insurance. The Company (a) shall maintain from financially sound and reputable insurers Directors and
Officers liability insurance and commercial liability insurance, each in an amount and on terms and conditions satisfactory to the Board of Directors, and (b) shall use its commercially reasonable efforts to obtain within ninety (90) days
of the date hereof from financially sound and reputable insurers “key person” insurance on Paul Badawi and David Badawi in an amount equal to at least $1,000,000 per person on terms and conditions satisfactory to the Board of Directors,
and will use commercially reasonable efforts to cause such insurance 

  
 17 

 
policies to be maintained until such time as the Board of Directors determines that such insurance should be discontinued; provided, that the “key person” insurance described in
this Section 3.5 shall not be discontinued without the affirmative vote of at least two (2) Preferred Directors. 

3.6    Employee Stock. Unless otherwise approved by the Board of Directors, all future employees and consultants of
the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for
(a) vesting of shares over a four (4)-year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly
installments over the following thirty-six (36) months; (b) a market stand-off provision substantially similar to that in Section 2; (c) the Company to have a
right of first refusal on transfers of shares until the Initial Offering; and (d) the Company to have the right to repurchase unvested shares at cost upon termination of the employment or consulting relationship of a holder of restricted stock.

 3.7    Employees and Consultants. The Company shall require all employees and consultants to enter into the
Company’s standard form of proprietary information and inventions agreement. 
 3.8    Board Matters. The
Company shall maintain an audit and compensation committee, consisting solely of non-management directors. Each non-employee director shall be entitled in such
person’s discretion to be a member of any committee of the Board of Directors. The Company shall take all requisite actions to alter the number of authorized members of the Board of Directors immediately following an Initial Offering to be no
less than seven (7) and no greater than nine (9) (the “IPO Board Size”). Following the Initial Closing (as defined in the Series F Purchase Agreement), the Board of Directors, the Investors, the holders of the then outstanding shares
of Common Stock, the then serving Chief Executive Officer, and the then serving Chief Financial Officer shall collectively use their commercially reasonable efforts to achieve the IPO Board Size. 

3.9    Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges
into any other entity and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the
obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Certificate of Incorporation,
or elsewhere, as the case may be. 
 3.10    FCPA. The Company shall not (and shall not permit any of its
subsidiaries or affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to,
directly or indirectly, to any third party, including any Non-U.S. Official (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case, in
violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further shall (and shall cause each of its subsidiaries and affiliates to) cease all of its or their respective activities, as well
as remediate 

  
 18 

 
any actions taken by the Company, its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in
violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. 

3.11    Termination of Certain Covenants. The covenants set forth in this Section 3, except for
Section 3.9, shall terminate and be of no further force or effect upon the earlier of the consummation of the Initial Offering or at such time as the Company is required to file reports pursuant to Sections 13 or 15(d) of the 1934 Act.
This Agreement, except for Section 3.9, shall terminate and be of no further force or effect upon the consummation of a transaction or series of related transactions which are deemed to be a liquidation, dissolution or winding up of the Company
pursuant to the Restated Certificate. 
 4.    Miscellaneous. 

4.1    Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall
inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any shares of Preferred Stock). Nothing in this Agreement, express or implied, is intended to confer upon any party other than
the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

4.2    Governing Law; Venue. This Agreement is to be construed in accordance with and governed by the internal laws
of the State of Delaware without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of Delaware to the rights and duties of the parties. All disputes and
controversies arising out of or in connection with this Agreement shall be resolved exclusively by the state and federal courts located in the State of California, and each party hereto agrees to submit to the jurisdiction of said courts and agrees
that venue shall lie exclusively with such courts. 
 4.3    Specific Enforcement. Each party hereto agrees that
its obligations hereunder are necessary and reasonable in order to protect the other parties to this Agreement, and each party expressly agrees and understands that monetary damages would inadequately compensate an injured party for the breach of
this Agreement by any party, that this Agreement shall be specifically enforceable, and that, in addition to any other remedies that may be available at law, in equity or otherwise, any breach or threatened breach of this Agreement shall be the
proper subject of a temporary or permanent injunction or restraining order, without the necessity of proving actual damages. Further, each party hereto waives any claim or defense that there is an adequate remedy at law for such breach or threatened
breach. 
 4.4    Counterparts. This Agreement may be executed in two or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument. 
 4.5    Titles and
Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 

  
 19 

 4.6    Notices. Except as may be otherwise provided herein, all
notices, requests, waivers and other communications made pursuant to this Agreement shall be in writing and shall be conclusively deemed to have been duly given (a) when hand delivered; (b) when sent by facsimile if sent between 8:00 a.m.
and 5:00 p.m. recipient’s local time on a business day, or on the next business day if sent by facsimile other than between 8:00 a.m. and 5:00 p.m. recipient’s local time on a business day; (c) three business days after deposit in the
U.S. mail with first class or certified mail receipt requested postage prepaid; or (d) the next business day after deposit with a national overnight delivery service, postage prepaid, with next business day delivery guaranteed, provided
that the sending party receives a confirmation of delivery from the delivery service provider. Each person making a communication hereunder by facsimile shall promptly confirm by telephone to the persons to whom such communication was addressed each
communication made by it by facsimile pursuant hereto but the absence of such confirmation shall not affect the validity of any such communication. All communications made pursuant to this Agreement shall be sent to the respective parties at their
addresses set forth on the signature pages hereto; provided, that a party may change or supplement its addresses, or designate additional addresses, for purposes of this Section 4.6 by giving the other parties written notice of the new
address in the manner set forth above. 
 4.7    Expenses. If any action at law or in equity is necessary to
enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

4.8    Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this
Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Investors holding a majority of the then outstanding Registrable Securities;
provided, however, that if any amendment or waiver operates in a manner that treats any Investor different, in any material respect, from other Investors, the consent of such Investor shall also be required for such amendment or waiver
and; provided further, that (i) Section 3.3 may only be amended or waived with the written consent of D1, (ii) Section 3.4 and this subpart (ii) may only be amended or waived with the prior written consent of D1 and the Janus
Investors, (iii) the definition of “Affiliate” (as it pertains to the Janus Investors), the definition of “Janus Investors” and this subpart (iii) may only be amended or waived with the prior written consent of the
Janus Investors, and (iv) the definition of “Affiliate” (as it pertains to D1), the definition of “D1” and this subpart (iv) may only be amended or waived with the prior written consent of D1. Any amendment or waiver
effected in accordance with this paragraph shall be binding upon each Investor and the Company. 
 4.9    Additional
Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the Company’s Series F Preferred Stock after the date hereof, any purchaser of such shares of Series F Preferred Stock shall
become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and thereafter shall be deemed an “Investor” for all purposes hereunder. The Company shall promptly update
Schedule A to reflect such purchaser as a party hereto. 
 4.10    Severability. If one
or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be
enforceable in accordance with its terms. 

  
 20 

 4.11    Aggregation of Stock. All shares of Registrable
Securities held or acquired by entities advised by the same investment adviser and Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

4.12    Termination of Prior Agreement. Upon the effectiveness of this Agreement, the Prior Agreement shall
terminate and be of no further force or effect, and shall be superseded and replaced in its entirety by this Agreement. 

4.13    Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement among
the parties with respect to the subject matter hereof and no party shall be liable or bound to any other party in any manner by any warranties, representations or covenants except as specifically set forth herein or therein. 

*          *          * 

  
 21 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
above written. 
  

			
	COMPANY:
	
	SIGHT SCIENCES, INC.
		
	By:	 	 /s/ Paul Badawi

	Name:	 	Paul Badawi
	Title:	 	President
	
	Address:
	4040 Campbell Ave.
	Menlo Park, CA 94025
	
	Email: XXX@sightsciences.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	D1 Master Holdco I LLC
	By:	 	D1 Capital Partners Master LP,
	its Managing Member
		
	By:	 	D1 Capital Partners GP Sub LLC,
	its General Partner
	
	 /s/ Daniel Sundheim

	     Daniel Sundheim
	     Authorized Signatory
	
	Address: c/o D1 Capital Management LC
	9 West 57th Street
	36th Floor
	New York, NY 10019
	
	with a copy to (which shall not constitute notice to):
	
	Sidley Austin LLP,
	787 Seventh Avenue,
	New York, NY 10019,
	Attention: Geoff Levin,
	Facsimile: 212-839-5599
	E-mail: XXX@sidley.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	Janus Henderson Venture Fund
	
	By: Janus Capital Management LLC, its
	investment advisor
		
	By:	 	 /s/ Jonathan Coleman

	Name:	 	Jonathan Coleman
	Title:	 	Authorized Signatory
	
	Janus Henderson Capital Funds plc on behalf of its series Janus Henderson US Venture Fund
	
	By: Janus Capital Management LLC, its
	investment advisor
		
	By:	 	 /s/ Jonathan Coleman

	Name:	 	Jonathan Coleman
	Title:	 	Authorized Signatory
	
	Address:
	Janus Capital Management LLC,
	151 Detroit Street
	Denver, CO 80206
	Attn: Jonathan Coleman (Email:
	XXX@JanusHenderson.com)
	Attn: Scott Stutzman (Email:
	XXX@JanusHenderson.com)
	Attn: Angela Morton (Email:
	XXX@janushenderson.com)
	
	with a copy, which shall not constitute notice, to:
	
	Perkins Coie LLP
	3150 Porter Drive
	Palo Alto, CA 94306
	Attn: Adrian Rich (Email:
	XXX@perkinscoie.com)

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	KCK Ltd., a British Virgin Islands
	limited company
		
	By:	 	 /s/ Nael Kassar

	Name:	 	Nael Kassar
	Title:	 	Director
	
	Address:
	Dubai Airport Free Zone
	Bldg. 5, Block A, 5th Floor, Office No. 512
	P.O. Box 29506
	Dubai, UAE
	
	Email:
	
	with a copy to:
	
	DLA Piper LLP (US)
	701 Fifth Avenue, Suite 6900
	Seattle, WA 98104-7044
	Attention: Tyler K. Hollenbeck

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	MIDCAP FUNDING XXVII TRUST
	
	By: Apollo Capital Management, L.P., its
	investment manager
	
	By: Apollo Capital Management GP, LLC, its
	general partner
		
	By:	 	 /s/ Maurice Amsellem

	Name:	 	Maurice Amsellem
	Title:	 	Authorized Signatory
	
	c/o MidCap Financial Services, LLC, as Servicer
	7255 Woodmont Avenue, Suite 300
	Bethesda, MD 20814
	Attention: Legal Group
	E-mail: legalamidcapfinancial.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	HH SIGHT PARTNERS, L.P.,
	a Texas limited partnership
	
	By: HH Sight Partners GP, L.P.,
	Its: General Partner
	
	By: HH Sight, LLC,
	Its: General Partner
		
	By:	 	 /s/ Mack H. Hicks

	Name:	 	Mack H. Hicks
	Title:	 	Co-President
	
	Address:
	2200 Ross Avenue, Fiftieth Floor
	Dallas, TX 75201
	Email: XXX@hicksholdings.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	HH-IOP PARTNERS, L.P.,
	a Texas limited partnership
	
	By: HH Sight Partners GP,
	L.P., Its: General Partner
	
	By: HH Sight, LLC,
	Its: General Partner
		
	By:	 	 /s/ Mack H. Hicks

	Name:	 	Mack H. Hicks
	Title:	 	Co-President
	
	Address:
	2200 Ross Avenue, Fiftieth Floor
	Dallas, TX 75201
	Email: XXX@hicksholdings.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	ALLEGRO INVESTMENT FUND, L.P.
		
	By:	 	 /s/ Staffan Encrantz

	Name:	 	Staffan Encrantz
	Title:	 	As Investment Manager for the General Partner
	Address:	 	525 Middlefield Road, suite 20
		 	Menlo Park, CA 94025
		
	Telephone:	 	  

		
	Facsimile:	 	  

		
	Email:	 	XXX@allegroinvestment.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	ALLEGRO INVESTORS LLC
		
	By:	 	 /s/ Staffan Encrantz

	Name:	 	Staffan Encrantz
	Title:	 	As Investment Manager for the General Partner
	Address:	 	525 Middlefield Road, suite 20
		 	Menlo Park, CA 94025
		
	Telephone:	 	  

		
	Facsimile:	 	  

		
	Email:	 	XXX@allegroinvestment.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	SCIENTIFIC HEALTH DEVELOPMENT II, LTD
	
	By: SHD GP II, LLC
	Its: General Partner
	
	By: /s/ Andrew Offer
	
	Name: Andrew Offer
	Title: CEO
	
	Address:
	2305 Cedar Springs, Suite 240
	Dallas, TX 75201
	Email: XXX@shdpartners.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	SIGHT SCIENCES ANGELS, LP
	
	By: ShervKo, LLC
	Its: General Partner
	
	By: /s/ Jesse Selnick
	
	Name: Jesse Selnick
	Title: Managing Member
	
	Address:
	1080 S. Adams
	Denver, CO 80209
	Email: XXXk@gmail.com

  
 SIGNATURE PAGE TO SERIES
F – THIRD AMENDED AND RESTATED INVESTORS’ 
 RIGHTS AGREEMENT 

 SCHEDULE A 

INVESTORS 
 Al G. Hill Jr. Family Trust,
dated December 20, 2014 
 Al G. Hill, Jr. 
 Allegro
Investment Fund, L.P. 
 Allegro Investors LLC 
 Andrew Offer

 Armour Trust 
 Bryan Goolsby 

Carter Meyer 
 Colonnetta Family Partners I, L.P. 

Dikigoros Holdings LLC 
 D1 Master Holdco I LLC 

Deirdre Porter Living Trust 
 E. Grant Fitts 1994
Grandchildren’s Trust 
 E.C. Coppola Family Limited Partnership 

Edward C. Coppola, Jr. 
 EGF Investments, LP 

Equity Trust Company, Custodian FBO Jeff Peterson IRA 
 Genus
Holdings, L.L.C. 
 HH Sight Partners, L.P. 
 HH-IOP Partners, L.P. 
 James C. Gorton 

James Parks 
 Janus Henderson Venture Fund 

Janus Henderson Capital Funds plc - Janus Henderson US Venture Fund 

Jerald T. & Emily Z. Baldridge Revocable Trust 
 KCK Ltd. 

MidCap Funding XXVII Trust 
 Pensco Trust Co. Custodian FBO Jordan
C. Meyer IRA 
 Peregrine Investments Limited 
 Samson
Investments, LLC 
 Scientific Health Development II, Ltd 
 SHD
Sight Sciences-18 LP 
 Sight Sciences Angel LP 

Stark 2010 Family Trust 
 Stephen ones 

The Brendan Iribe Group X, LLC 
 Thomas C. Unis 

Timothy P. Rooney 
 VP Company Investments 2018, LLC 

William Munck

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]